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ABSTRACT
Staphylococcus aureus is a common human pathogen that is responsible for a
wide range of infections, ranging from relative minor skin infections to life-threatening
disease such as bacteremia, septicemia, and endocarditis. S. aureus possesses many
different virulent factors that aid in its ability to cause this wide array of infections. One
major virulence factor includes the production of capsular polysaccharide (CP). The
production of CP plays a major role in the virulence response during infection
specifically by providing S. aureus an antiphagocytic mechanism that allows the
pathogen to evade phagocytosis during an infection. S. aureus has developed complex
genetic regulatory systems responsible for controlling virulence factors including CP.
The production of CP is encoded by a 16-gene operon, which is regulated in response to
several environmental stimuli. In detail, CP is produced in the late- and post-exponential
growth phases in vitro, but not in the early- or mid-exponential growth phases. Several
genetic regulators have been identified to be involved in controlling CP production, but
the mechanisms involved in this regulation of cap are still poorly understood. In this
work, we describe that the msaABCR operon significantly regulates CP production. We
found that a protein product of the msaABCR transcript, MsaB, directly binds to a
nucleotide repeat upstream of the promoter region of the cap operon, termed MsaB
binding site or (MBS), as a transcriptional activator of CP production. Furthermore, we
show that even though MsaB is expressed throughout all four exponential growth phases,
it only activates CP production in the late- and post-exponential growth phases. Several
other regulators have also been shown to directly bind within the cap promoter region.
We examined potential interactions between MsaB and two other nutrient-sensing
ii

regulators, CodY and CcpE, binding the cap promoter. From the findings of this work,
we have concluded that MsaB (activator) and CodY (repressor) have nutrient-dependent
competitive interactions binding to the cap promoter. Findings from this work has led us
to explore targeting and inhibiting MsaB transcriptional regulation as a potential novel
therapeutic target in combating S. aureus.
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CHAPTER I – INTRODUCTION
1.1 The Biological Characteristics of Staphylococcus aureus
Staphylococcus aureus (S. aureus) is a Gram-positive cocci bacterium belonging
to the phylum Firmicutes, class Bacilli, and order Bacillales. The bacterium is a catalase
and coagulase positive cocci, measuring about 0.7 – 1.2 µm in diameter. The term
“staphylococcus” was derived from the Greek word “staphyle”, meaning bunch of grapes
and the term “coccus” meaning grain or berry, as a result of its clustered appearance
under a microscope. Its early history started in 1878 when Robert Koch first observed
that the formation of abscesses is strongly correlated with the presence of Gram-positive
cocci. Shortly after in 1884, Rosenbach came up with a method to differentiate species of
staphylococci based on colonial pigmentation. He noted that the more virulent species
formed golden colonies compared to the less virulent species which formed white
colonies. Later in 1904, Leo Loeb reported that select staphylococci had the ability of
influencing the coagulation process of blood. This has later been developed into the
current method of typing used to differentiate the species of staphylococci which is
commonly known as the coagulase test. S. aureus is the only staphylococci species that
has the ability to convert fibrinogen into fibrin which results in the cells clumping
together. As a result, a positive coagulase test confirms the identity of Staphylococcus
aureus.
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Figure 1.1 A Representative Image of S. aureus Displayed Under Microscope.
The characteristic clumping behavior of staphylococci is evident in this figure. (Content source: Centers for Disease Control and
Prevention)

S. aureus has the ability to grow in a wide range of conditions (1, 2). This ability
helps make it a very successful organism in which it is necessary for survival in the
environment outside of a host as well as within a host organism when infection is
established. S. aureus optimal growing conditions are under aerobic conditions and in the
presence of CO2. However, it is also capable of surviving in environments with very low
concentrations of oxygen such as in different stages of an infection including biofilm and
within low oxygen levels in different locations within the host (3).
S. aureus is studied extensively due to its clinical importance to human health. S.
aureus normally resides in healthy individuals as part of the normal flora colonizing the
nose, throat, armpit, groin, and intestinal tract. However, when the bacterium is
introduced into a skin incision or wound, it has the ability to cause infections. S. aureus is
one of the most common causes of hospital acquired infections which is responsible for
approximately 80,000 invasive Methicillin Resistant staphylococcus aureus (MRSA)
infections that leads to approximately 11,000 deaths each year in USA (CDC, 2014).
2

Much work has been performed on S. aureus in efforts to understand its success
throughout its evolutionary history and to attempt to understand the molecular basis of its
virulence processes.
It is commonly observed that S. aureus begins to colonize the human body during
the early childhood years and is typically carried throughout the individual’s life. It is
estimated that approximately 30% of the healthy population in the USA carry S. aureus
in the nasal passage (4, 5). This colonization is achieved by the ability to rapidly adhere
to the nasal mucosa surfaces. This adherence is mediated through several surface protein
adhesins including clumping factors, and fibronectin binding proteins (6-9). S. aureus
possessed many surface associated proteins that aid in the ability to bind a broad range of
host tissues such as the binding to epithelial and endothelial cells as well as mucosal
surfaces and intercellular matrix proteins within the host (10).
The recent rise of MRSA infections is responsible for a widespread problem in
public health. MRSA infections causes about 20,000 hospitalizations and is estimated to
be responsible for more than 1 billion dollars in healthcare costs in the USA annually.
Initially, MRSA samples were typically isolated to the hospital setting and were referred
to as hospital-acquired MRSA (HA-MRSA). These types of infections were common in
patients with prior history of medical treatments especially prior exposure to antibiotics.
However, in the recent past, S. aureus infections have begun to emerge in the community
setting without any association or link to hospitalization. These types of infections are
labeled as community-acquired MRSA (CA-MRSA) and are particularly important due to
the fact that these infections can potentially cause serious disease in individuals who were
3

otherwise healthy and had no direct means of infection such as hospitalization. Currently,
the United States is in the middle of an epidemic caused by CA-MRSA isolates. Much
research has been performed on these types of infections however, much work still needs
to be done as we are just beginning to uncover the mechanisms of virulence that this
pathogen utilizes to cause infection as well as continuing to understand the evolutionary
complexity of this organism.
1.2 Major Virulence Factors of Staphylococcus aureus
Staphylococcus aureus is an opportunistic human pathogen that is known for its
capacity to cause a wide variety of infections in humans ranging from relatively minor
superficial skin infections to life threatening diseases such as osteomyelitis, endocarditis,
and bacteremia or septicemia (11, 12). The ability of this pathogen to cause such
infections relies on the many virulence factors that it possesses (13). These virulence
factors participate in the pathogenesis of the infection process and allow the bacterium a
mechanism to avoid or invade the response of the host immune system. S. aureus
virulence determinates can be divided into two major categories including cell-surfaceassociated or (adherence) and secreted factors or (exotoxins) (14). Two of the major
contributors of virulence possessed by S. aureus that is in the scope of this work includes
the production of capsule polysaccharide or (CP) and the production of biofilms.
The production of capsule has been shown to play a major role in virulence during
infection by aiding in the pathogens survival particularly as a means to escape
phagocytosis (15-17). This is particularly important for the pathogens survival in acute
phases of infections such as bacteremia or septicemia (16, 18-22). Capsule has been
proposed to act primarily as an anti-phagocytic factor that allows the pathogen to persist
4

and escape phagocytic uptake during movement from one localized site to another in the
course of an infection or in circulation through the blood stream (16). Other findings
suggest that capsule does not always prevent phagocytosis from occurring but rather,
through an undetermined mechanism, aids in the ability of the bacterium to survive
within the polymorphonuclear neutrophils (PMNs) after ingestion has occurred (23).
Another prospected role of capsule in disease is that the fine tuning of CP production is
essential when the infection is progressing to a more chronic long term infection (24).
Initial adherence to surfaces is facilitated by reducing CP production which exposes
adhesins. After adherence is achieved, the bacterium can then proceed to internalization
within the host cell where it can readily escape elimination from immune system
components (24). Likewise, the transition to a chronic infection often requires the ability
of adherence to host tissue or internalization into a host cell. In this course it is speculated
that the production of capsule must be fine-tuned and significantly reduced for a
population to be selected for that does not produce capsule to achieve the adherent
phenotype (24).
Another important aspect of staphylococcal infections is biofilm development
within the host. Biofilm associated infections can be particularly difficult to treat due to a
high tolerance to antimicrobial agents as well as the ability of the cells to escape immune
system components. As a result, production of biofilm renders the bacterium resistant to
the host’s immune response as well as antimicrobial agents. Biofilm formation has been
shown to be responsible for the establishment of chronic infections such as osteomyelitis,
infective endocarditis, indwelling-medical-device-associated infections, and chronic
wound infections (11, 25, 26). Staphylococcus aureus produces a very well-organized,
5

multilayered, three-dimensional mushroom-shaped biofilm embedded in an
extrapolymeric matrix composed of poly-N-acetylglucosamine (PIA), extracellular DNA
(eDNA), and several heterogeneous proteins (3, 27-31). This extracellular matrix found
within the biofilm allows for the sequestering and concentration of environmental
nutrients and provides resistance to external antimicrobial compounds as well as helps in
the evasion of host immune system clearance strategies including escape from
phagocytes, shear stress, and host proteases (32, 33). The cells growing within the
biofilm consists of a diverse population with different metabolic states including aerobic,
fermentative, dormant, and dead cells, depending upon their location within the biofilm
structure. Most cells found within the internal layers of biofilms are dormant and exist
under anoxic conditions, making them tolerant of high concentrations of antimicrobial
drugs (34, 35).
1.3 Genetic Regulatory Networks in Staphylococcus aureus
The expression of the virulence factors possessed by S. aureus including CP
production and biofilm formation, as well as the others, are coordinated by a complex
network of global genetic regulators. Some of these major regulators such as the Agr
system, Sae, and Sar have been studied extensively and characterized in their role in the
regulation of virulence. The Agr system has been shown to regulate the expression of
numerous virulence genes (36). The Agr system’s mechanism of regulation is largely
dependent upon an RNA molecule, termed RNAIII, that is produced in response to
quorum sensing which regulates gene translation (37, 38). This RNA molecule possesses
a relatively unique feature in the fact that it may act as a repressor or an activator
dependent on different conditions of regulation (39). The Sae locus or (staphylococcal
6

accessory element) is a two-component regulatory system that consists of four elements.
These elements include SaeP, SaeQ, SaeR, and SaeS. The functions of SaeP and SaeQ
remain unknown within the system (40). The SaeR and SaeS components are both the
response regulators through a histidine kinase mechanism of the two-component system
(41). The Sae system has been shown to control the transcription of many secreted factors
and adhesins in S. aureus and has been shown to be activated by the presence of human
neutrophil proteins (10, 42-49). The SarA locus or (staphylococcal accessory regulatory
locus) was identified by screening an insertional mutant library for a decrease in exotoxin
production in S. aureus (50). The sarA gene encodes for a 15 kDa protein SarA (51).
This gene has been determined to be controlled by three identified promoters P1, P2, and
P3 that generates three different transcripts (52, 53). These different transcripts tend to
be differentially expressed during different phases of growth, however the SarA protein is
produced in similar amounts during all phases of growth (54). SarA has been shown to
up-regulate as well as down-regulate many virulence determinates within S. aureus (50,
54-59). Additionally, SarA has been shown to be crucial for biofilm formation which is a
very important virulence determinate as described above. The mechanism of this has
been found to be largely related to SarA inducing the expression of the ica operon which
is a major factor responsible for biofilm formation in S. aureus (60, 61).
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Figure 1.2 A Representative Image of Major Global Regulators in S. aureus.
Guillet J. et al. Emerging Functions for the Staphylococcus aureus RNome, (2013). (62)

Additionally, there are many newly identified regulators that require further study
to determine their exact role in the virulence process. One of these identified regulators
and the main focus of our work is a regulator originally termed msa or (modulator of
sarA) (63, 64). We have recently identified that msa is working together with two other
genes upstream in an operon that we have now termed msaABCR. The msaABCR operon
has been shown to modulate the expression of sarA and agr which are main global
regulators that controls the expression of genes involved in virulence and biofilm
development (65, 66). The msaABCR operon has also been shown to be playing a role in
antibiotic resistance specifically with resistance to vancomycin (67). The findings thus far
are beginning to describe the global regulation that the msaABCR operon is responsible
8

for controlling. However, much more work is required to fully understand and describe
the mechanism of its regulation. This work as well as work on other major global genetic
regulators is necessary for an in depth understanding of S. aureus global regulatory
networks and is necessary to fully understand its array of virulence factors and to devise
future novel treatment methods against this pathogen.

Figure 1.3 A Representative Image of msaABCR as a Regulator in S. aureus.
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CHAPTER II – THE MSAABCR OPERON REGULATES CAPSULE
POLYSACCHARIDE PRODUCTION IN STAPHYLOCOCCUS AUREUS
2.1 Introduction
Staphylococcus aureus is an opportunistic human pathogen that causes a wide
variety of infections, ranging from relatively minor superficial skin infections to lifethreatening diseases, such as osteomyelitis, endocarditis, and bacteremia or septicemia
(11, 12). The ability of this pathogen to cause such infections relies on its many virulence
factors and their coordinated regulation (11, 13, 68-71). One of the major virulence
factors is the production of the capsular polysaccharide (19). The production of the
capsule has been shown to play a major role in bacterial virulence during infection by
facilitating the pathogen’s survival inside the host, and particularly as a way to escape
phagocytosis (15-17). Several attempts have been made to produce an effective vaccine
to protect individuals at risk of S. aureus infection. Normal human serum contains low
levels of antibodies specific for the S. aureus CP5 and CP8 antigens (72), and several
animal models of infection have shown that the addition of antibodies specific for capsule
serotypes confers some level of protection against S. aureus (72, 73). However, other
groups, using different models, have found that no protection was conferred by the
addition of CP-specific antibodies (74). These findings suggest that the efficiency of
antibodies specific for capsule in eliminating S. aureus is based on the type of infection
model used. Specifically, in the study by Lee et al. (1997) a modified method of route of
inoculum was used in a rat infective endocarditis model. The modified method included a
challenge using intraperitoneal injection route to achieve slow infusion of S. aureus into
the blood compared to intravenous challenge used by other studies (73, 74). This is
10

probably attributable to the fact that the capsule is only produced under certain
experimental conditions and under specific conditions associated with the infection
process. Staphylococcus aureus produces four main serotypes of capsule, including the
heavily encapsulated serotypes CP1 and CP2 and the microcapsulated serotypes CP5 and
CP8. However, in the clinical context, serotypes CP5 and CP8 are considered most
significant and account for 70–80% of clinical isolates (75-77). The production of the
capsule plays a major role in the virulence response during infection by facilitating the
pathogen’s survival, particularly during the acute phase of certain types of infection,
including bacteremia (16, 18-22). The capsule is proposed to act primarily as an
antiphagocytic factor that allows the pathogen to persist and escape phagocytic uptake
during its movement from one localized site to another in the course of infection or
during its circulation through the bloodstream (16). Other studies have suggested that the
capsule does not prevent phagocytosis but instead, through an undetermined mechanism,
improves the ability of the bacterium to survive within the polymorphonuclear
neutrophils (PMNs) after it has been ingested (23). Another hypothesis on the role of the
capsule in disease is that the fine-tuning of capsule production is essential when the
infection is progressing to a more chronic long-term infection (24). The initial adherence
of the bacterium to surfaces is facilitated by the downregulation in capsule production.
When no capsule is present, cell adhesins are exposed on the surfaces of cells. This
allows the bacterium to adhere to a surface or a host cell. After adherence to the host cell
is achieved, the bacterium can then proceed to internalize within it, where it can readily
escape elimination from the components of the host immune system (24). Regardless of
the mechanism, it is clear that the production of the capsule is involved in bacterial
11

pathogenesis by enhancing the ability of the bacterium to survive during the acute phase
of infection and in the transition to the chronic stage of infection by either resisting
phagocytosis or surviving after ingestion (16, 18-24).
Capsule production is encoded by a single operon composed of 16 genes (78, 79).
The genes that encode the CP5 and CP8 serotypes are very similar, including serotypespecific genes that are flanked by common, nearly identical genes (80). Given the
similarity in the gene sequences of these two serotypes, it is inferred that the regulation of
capsule production in the two serotypes is also similar (80). Indeed, the cap operons of
these two serotypes have nearly identical promoters, which are located directly upstream
from the capA open reading frame (ORF) (78). The regulation of capsule production is
complex and depends on the bacterial growth phase. Capsule production is suppressed in
the early- and mid-exponential growth phases but is activated in the late- and postexponential growth phases (81-83). Furthermore, some strains do not produce capsule in
liquid medium but do so when grown on solid medium (81). Other reports have shown
that the iron concentration in the medium or environment regulates capsule production
(81, 84), and the CO2 concentration has been shown to regulate capsule production in
both in vitro and in vivo models of infection, in a strain-dependent fashion (85, 86).
Despite the various environmental conditions that regulate capsule production,
very little is yet known about the specific regulators that control the expression of the cap
operon. Several global regulators have been shown to control the production of the
capsule, including agr, sarA, arl, and mgrA as well as others (87-93). A detailed analysis
of the cap operon promoter has revealed that it is highly regulated (78), Indeed, a 10-bp
inverted repeat that is located directly upstream from the promoter is essential for the
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regulation of the transcription of the cap operon. Based on mutagenesis analyses, this 10bp inverted repeat region is predicted to be a binding site for a regulator (activator or
repressor) (78). Studies have shown that capsule production is highly regulated. Indeed,
several regulatory proteins have been shown to bind to the promoter region of the cap
operon. These include, the two-component systems AirSR, KdpDE, and SpoVG as well
as nutrient sensing regulatory proteins CcpE and CodY (94-98). CodY is the best-studied
cap regulatory protein and has been shown to sense nutrient availability, such as
branched-chain amino acids and GTP, during the different phases of bacterial growth.
The binding affinity of CodY is highest in an excess of amino acids and GTP, and as the
intercellular pools decrease, the binding affinity of CodY decreases, resulting in a
derepression effect (99-101). Recently, a new DNA-binding regulator, RbsR, has been
shown to bind to the cap promoter region and to activate transcription of the cap operon.
RbsR is controlled directly by the alternative sigma factor SigB (102).
We previously identified the msaABCR operon, which is involved in the
regulation of virulence, biofilm development, and antibiotic resistance in S. aureus (6365, 67, 103). The deletion of the msaABCR operon alters the expression of several global
regulators, including sarA, agr, and sigB, all of which have been shown to be indirectly
involved in capsule production (65, 87, 92, 104-106). The regulatory mechanism for
msaABCR has not yet been defined. In this study, we show that msaABCR is essential for
capsule production, and that MsaB is a transcriptional activator of the cap operon,
binding specifically to the 10-bp inverted repeat located upstream from the cap operon.
We also show that the regulation of capsule production is analogous in both clinical
serotypes CP5 and CP8.
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2.2 Methods
2.2.1 Bacterial strains and growth conditions
We used a representative strain for each of the two clinically significant capsule
serotypes, CP5 and CP8. The S. aureus strains used in this study were Mu50, a known
vancomycin-intermediate S. aureus (VISA) isolate that produces capsule serotype 5, and
UAMS-1, a vancomycin-sensitive S. aureus (VSSA) osteomyelitis isolate that produces
capsule serotype 8. A restriction-deficient laboratory strain of S. aureus, RN4220, and the
DH5 strain of Escherichia coli were used to move plasmid constructs into the strains of
choice through transformation and phage transduction, as described previously (65, 67,
107). S. aureus strains were grown in tryptic soy agar (TSA) or tryptic soy broth (TSB),
as appropriate. When required, either erythromycin (10 g mL–1) or chloramphenicol (10
g mL–1) was added to TSB or TSA for selection. The E. coli strain was grown in Luria–
Bertani (LB) medium, with added ampicillin (100 g mL–1) when required.
2.2.2 Generation of deletion mutants and complementation
The allelic replacement method was used to generate the msaABCR and msaB
deletion mutants in strains Mu50 and UAMS-1 (107). For trans-complementation, the
msaABCR region was cloned into the pCN34 low-copy vector with the modification of
changing the Kanamycin selectable marker to a Chloramphenicol resistant marker as
described previously (67, 108). The capsule mutant was generated by insertion of the
transposon in capA ORF. Briefly, strain NE302 (SAUSA300 0152) was obtained from
the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) collection
(bei Resources, Manassas VA). This strain contains the bursa aurealis mariner-based
erythromycin resistance-expression transposon within the encoding capA region. The
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mutation was moved by generalized transduction using bacteriophage Φ11(63, 67).
Introduction of capA::Tn mutation was verified by PCR, sequencing and capsule
production assay.
2.2.3 RNA extraction, reverse transcription, and qRT-PCR
The expression of the capE gene was measured with qRT–PCR in both wild-type
strains and their corresponding mutants (109). Briefly, an aliquot of an overnight culture
was normalized to an optical density at 600 nm (OD600) of 0.05 and then grown to the
late-exponential/post-exponential phase for optimal capsule production. After the cells
had grown to the appropriate phase, they were pelleted with centrifugation, treated with
RNAprotect™ Bacteria Reagent (Qiagen, Valencia CA), and stored at –80 °C until
analysis. The samples were thawed on ice and total RNA was extracted as previously
described (65, 67). qRT–PCR was performed and the relative fold change in gene
expression was calculated using gyrA as the internal control (65, 67, 110).
2.2.4 Absolute quantification of the msaB transcript
Absolute quantification of the msaB transcript was performed by the method
previously described by Chini et al. (111) . Briefly, the msaB and gyrA genes were
amplified from chromosomal DNA using primers external to the primers used for
quantitative reverse transcription qRT-PCR. These amplicons were purified, and their
concentrations were measured using a Nanodrop spectrophotometer. The corresponding
concentrations were converted to copies per microliter by a previously described method
(112). Tenfold serial dilutions (range, 102 to 106) of these amplicons were used as
templates for qRT-PCR. Standard curves were generated by plotting threshold cycle (CT)
values against the log of the copy numbers (log starting quantity [SQ]). Starting
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quantities of “unknown” wild-type samples (early-, mid-, late-, and post-exponential
cDNA of Mu50 and UAMS-1) were calculated by plotting the respective CT values on
the standard curve. Copy numbers were measured by raising 10 to the power of the SQ
(10SQ). Copy numbers of msaB were normalized to those of gyrA and plotted. The
process was repeated in triplicate independently.
2.2.5 In vitro capsule production assay
Total capsule production was determined with a dot-blotting method described by
Luong et al. (88), with the following modifications. In brief, 2 mL of an 18-h culture,
adjusted to an OD660 of 5.0, was pelleted and resuspended in 100 µL of phosphatebuffered saline (PBS). The suspension was treated consecutively with the following
enzymes at 37 °C: lysostaphin (100 µg mL–1) for 15 min, DNase I (300 U mL–1) for 15
min, and proteinase K (100 µg mL–1) for 1 h. The proteinase K was subsequently
inactivated by heating at 75 °C for 10 min. The crude capsule preparations were assayed
by immunoblotting, as described previously (88).
2.2.6 In vitro whole blood survival assay
The survival of S. aureus in whole human blood was measured with an in vitro
method, as described by Nygaard et al. (113), with minor modifications. In brief,
heparinized venous blood samples were collected from healthy donors according to a
protocol approved by the Institutional Review Board for Human Subjects at The
University of Southern Mississippi. Staphylococcus aureus cells were harvested in the
post-exponential phase of growth (~9  1010) to ensure optimal capsule production. The
blood (3 mL) was inoculated with 3  105 S. aureus cells in a 14 mL culture tube and
incubated at 37 °C for 2 h with end-over-end rotation at 20 rpm. The samples were then
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diluted with sterile deionized water to lyse the blood cells and the CFUs were counted
after plating on TSA.
2.2.7 Human neutrophil phagocytosis assay
The phagocytosis of S. aureus by freshly isolated human PMNs was measured as
described previously (23), with the following modifications. In brief, PMNs (1  106)
were combined with S. aureus (1  107) in a 24-well tissue culture plate and centrifuged
at 380  g for 8 min to synchronize phagocytosis. The cells were then incubated for 2 h at
37 °C with 5% CO2. After incubation, the samples were plated on TSA and incubated
overnight at 37 °C. The colony-forming units (CFUs) were counted and the test samples
compared with the controls, which contained deionized water instead of the neutrophil
suspension. This assay measures the total number of viable uningested bacteria.
2.2.8 Construction of cap promoter-luxAB fusions and luciferase assays
The E. coli–staphylococcal shuttle vector pCN58 was used in this study, which
contains a low-copy-number staphylococcal replicon cassette (pT181copwt repC) and a
promoterless reporter gene, luxAB (encoding the luciferase from Vibrio fischeri),
constructed to analyze transcriptional fusions (108). The promoter region of the identified
cap promoter, including the 10-bp inverted repeat that was identified and described by
Ouyang et al. (78), were fused to luxAB for promoter studies in the msaABCR and msaB
mutants. To study the promoter–luciferase activity, overnight bacterial cultures were
diluted 1:10 in TSB and incubated for an additional 3 h. The cells were then normalized
to an OD600 of 0.05 and incubated further at 37 °C with shaking (220 rpm). The bacterial
cells (5 mL) were harvested in different phases of growth: OD600 of 1.0, 4.0, 7.0, or after
growth for 18-h, representing the early-, mid-, late-, and post-exponential growth phases,
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respectively. The cells were washed once with PBS and resuspended in 1 mL of PBS.
The cell suspensions were mixed with 100 L of 1% decanal (v/v) in 90% ethanol, and
their luminescence was measured with a luminometer immediately after mixing, using 10
s measurements in the integrated data mode. The luciferase activities were recorded in
relative luminescence units (RLUs), and the specific luciferase activities were calculated
by dividing the RLU values by the absorbance of the culture (RLU/OD600). The
promoterless version of the reporter-gene plasmid (pCN58) was used as the control.
2.2.9 Expression and purification of MsaB and antibody production
The msaB open reading frame (SAV1402) of S. aureus strain Mu50 was cloned
into the pH6HTNHis6HaloTag® T7 plasmid (Promega Corporation, Madison, WI) as an
XbaI–ApaI fragment. Escherichia coli strain BL21(DE3) was then transformed with the
resulting plasmid, pH6HTN–msaB, and the transformants were selected on LB agar
plates containing ampicillin. LB broth (1 L) with ampicillin (100 μg mL–1) was
inoculated with an overnight culture (10 mL) of a positive colony. Protein expression was
induced by adding isopropyl β-D-1-thiogalactopyranoside (IPTG) at a final concentration
of 0.5 mM. The cells were pelleted 4 h after induction and resuspended in PBS (pH 7.4)
with a protease inhibitor cocktail, and then lysed by sonication. The cell lysate was
centrifuged at 10,000  g for 30 min to remove the cell debris. The His6Halo–MsaB
fusion protein was purified from the clear lysate with a nickel column (HisPur™ Ni-NTA
Resin; Thermo Scientific, Rockford, IL). The fusion protein was then cleaved with the
Tobacco etch virus (TEV) protease (ProTEV Plus; Promega Corporation) to remove the
His6Halo tag. The cleaved protein band was excised from the polyacrylamide gel and
identified with mass spectrometry by a commercial company (MS Bioworks, Ann Arbor
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MI). The MsaB protein was purified from the tag with reversed-phase HPLC. After the
removal of acetonitrile by vacuum centrifugation, the protein was dissolved in PBS (pH
7.4) and stored for future use. Antibodies directed against MsaB were raised in a rabbit
by a commercial company (Thermo Scientific Pierce, Rockford IL).
2.2.10 Chromatin immunoprecipitation assay (CHIP) with anti-MsaB antibody
The ChIP assay was performed as described by Sengupta et al. (114), with minor
modifications. Briefly, exponentially growing S. aureus cells were treated with 1%
formaldehyde and 10 nM sodium phosphate to facilitate the cross-linking of MsaB to its
targets. After 20 min, the cross-linking reaction was quenched by the addition of 0.1
volumes of 3 M glycine. The cultures were then pelleted and washed with an equal
volume of 0.1 M phosphate buffer to remove excess formaldehyde. The phosphate buffer
was removed by centrifugation and the cells were resuspended in 200 µL of IP buffer (50
mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl
fluoride, 5% glycerol, 1% Triton X-100) and broken with bead beating. The cell lysates
were then diluted with 200 µL of IP buffer and the cellular DNA was sheared with
further bead beating. The cell debris was removed by centrifugation and the clear
supernatant was diluted with 1 mL of IP buffer. To 200 µL of the clear lysate, an antiMsaB antibody (diluted 1:1000) was added and incubated at room temperature for 2 h.
This antigen–antibody mixture was then added to prewashed Protein-G-coupled magnetic
beads (Thermo Scientific) and incubated under ambient conditions for 1 h. The antigen–
antibody–bead complex was collected with a magnetic tube holder, washed twice with
wash buffer (Tris-buffered saline, 0.05% Tween 20, 0.5 M NaCl), and then washed with
ultrapure water. The beads were resuspended in 100 µL of elution buffer (50 mM Tris19

HCl [pH 8.0], 1 mM EDTA, 1% SDS) and incubated at 65 °C overnight to reverse the
cross-links. The DNA was extracted with a phenol–chloroform extraction method. The
DNA was used as the template to detect the MsaB-bound promoter sequences with PCR
amplification using promoter-specific primers. The msaABCR operon mutant was used as
an internal negative control to demonstrate that the MsaB antibody enriches the cap
promoter region specifically.
2.2.11 Electrophoretic mobility shift assay (EMSA)
Duplex DNA fragments, 22 nucleotides in size, containing the 10-bp inverted
repeat described by Ouyang et al. (78) were synthesized and biotinylated at the 5 end by
a commercial source, (Integrated DNA Technologies, USA). The shift assays were
performed with the Light Shift Chemiluminescent EMSA Kit (Pierce, USA), according to
the manufacturer’s protocol. Briefly, the 5-biotinylated duplex fragments were incubated
with increasing concentrations of purified MsaB protein for 20 min at room temperature
in 20 µL of reaction buffer (1  binding buffer, 2.5% glycerol, 5 mM MgCl2, 50 ng mL–1
poly dI–dC, 0.05% NP-40). Unlabeled DNA probe was used in 10-molar excess as a
specific competitive binding control in the reaction. Additionally, a DNA probe that does
not contain the MsaB binding site (MBS) was used as a negative binding control in the
reaction. The samples were subjected to electrophoresis in a native 6.0% polyacrylamide
gel. The proteins in the gel were then visualized using the detection module supplied with
the kit, according to the manufacturer’s protocol, and imaged with the ChemiDoc™
System (BioRad) to detect any shifted band.
2.2.12 Western blotting and quantification of MsaB protein
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To measure the expression level of MsaB across the growth phases of Mu50 and
UAMS-1, quantitative western blotting was performed with whole-cell lysates. Overnight
cultures were normalized to OD600 = 0.05 and incubated at 37 °C. The cells were
harvested at OD600 = 0.7 (early), = 1.5 (mid), = 4.0 (late), or after overnight incubation
(post-exponential) and frozen until analysis. The pellets were resuspended in PBS with a
protease inhibitor and lysed with bead beating. The crude lysates were centrifuged to
remove the cell debris. The clear supernatants were collected and their protein
concentrations determined with the BCA method, using the Pierce™ BCA Protein Assay
Kit (Life Technologies, Grand Island, USA). The proteins (25 μg) from each sample were
loaded onto an SDS-polyacrylamide gel and separated. After the proteins were blotted
onto a polyvinylidene difluoride membrane, and blocked with 5% nonfat skim milk,
MsaB was detected with an anti-MsaB antibody and a peroxidase-conjugated secondary
antibody. The MsaB bands were quantified with the ImageJ software (115).
2.2.13 Altered nutrient experiments
The production of the capsule was measured under nutrient-altered conditions to
test the effects of the regulation of nutrients on capsule production. Briefly, the cultures
were subjected to different nutrient conditions in different growth phases. For the
nutrient-depleted conditions, overnight cultures were normalized to an OD600 of 0.05,
incubated at 37 °C with shaking (220 rpm), and allowed to grow to early-exponential
phase, when the cells were collected with centrifugation. The pellet was resuspended in
filter-sterilized overnight-spent medium and then incubated at 37 °C with shaking (220
rpm) for an additional two hours. The capsule production assay and ChIP assay were
performed as described above using mid-phase grown cells under normal conditions as
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controls for comparative analysis. For the nutrient-replenished conditions, overnight
cultures were normalized to an OD600 of 0.05, incubated at 37 °C with shaking (220 rpm),
and allowed to grow to late-exponential phase, when the cells were collected by
centrifugation. The pellet was resuspended in fresh growth medium (TSB) and incubated
further at 37 °C with shaking (220 rpm) for an additional two hours. Capsule production
was then assayed as described above using late-phase grown cells under normal
conditions as controls for comparative analysis.
2.3 Results
2.3.1 msaABCR operon is essential for capsule production
To investigate the role of the msaABCR operon in the regulation of capsule
production, we deleted the msaABCR operon in two strains, Mu50 and UAMS-1, that
represent the two most commonly encountered clinical serotypes, CP5 and CP8,
respectively. We first examined the expression of the capsule operon in both strains by
measuring the expression of the cap genes in four different growth phases using a
reporter fusion protein. As previously reported, both strains showed reporter activity only
in the post-exponential growth phase, whereas the msaABCR deletion mutant showed no
reporter activity in any of the four growth phases tested (Figure 2.1). This suggests that
the deletion of the msaABCR operon abolished the activation of the cap promoter. We
confirmed our findings by measuring the transcription of the capE gene, which is
required for capsule production, using qRT–PCR, and by directly measuring capsule
production with immunoblotting using anti-CP antibody (Figure 2.2 a,b). We found that
msaABCR is essential for the transcription of the cap operon and the production of
capsule in the post-exponential growth phase in both strains. Complementation of the
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deletion mutants with a functional copy of the msaABCR operon restored the
transcription of the operon and the production of the capsule in both strains to levels
similar to those in the wild type (Figure 2.2 a,b). This confirms that the msaABCR operon
is required for the production of the capsule in two different strains. These results
indicate that the msaABCR operon regulates the expression of the capsule operon very
tightly because the mutants showed no evidence of capsule production.

Figure 2.1 Luciferase transcriptional analysis of the CP5 and CP8 operon promoter
region.
cap operon promoter activity was measured in the wild types, msaABCR mutants, and msaB mutants of cap5 (a) and cap8 (b) in
different growth phases (early-, mid-, late-, and post-exponential phases). The vector pCN58 containing luxAB without a promoter was
used as a negative control. These results represent the means of three independent experiments. Bars represent standard errors.
Student’s unpaired t-test was used to compare the results of wild types to their respective mutants. The results were displayed by
asterisks using the following P value cutoffs: (NS P > 0.05, ** P ≤ 0.01, *** P ≤0.001)
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Figure 2.2 qRT-PCR relative fold change of cap operon genes and immunoblotting
measurement of total CP5 and CP8 production.
cap qRT–PCR was used to measure the relative fold changes in cap5E and cap8E in the mutants and the complemented mutants
compared with the wild type (a). Total CP production was assessed in the representative CP5 and CP8 strains, including their
respective mutants and complements of msaABCR (b) and msaB (c). Samples were serially diluted as indicated on the left and dotblotted directly onto the membrane. The blots were processed using CP5- and CP8-specific antibodies. These results are representative
of three independent experiments for each sample set.

The msaABCR operon is not yet fully defined. Although we have learned a
substantial amount about the phenotypes with which the operon is associated, we do not
yet have a clear picture of the contributions made by each gene. We have analyzed the
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structure of the msaABCR operon and found that it encodes three functional noncoding
RNAs (msaA, msaC, and msaR) that are essential for the function of the operon (65).
Additionally, we have found that MsaB is the only protein encoded transcript of the
msaABCR operon. We hypothesize that the three noncoding RNAs (msaA, msaC, and
msaR) act in concert to regulate the expression of MsaB, which likely functions as a
transcription factor (65). In this study, we examined the contribution of msaB to the
regulation of capsule production. We deleted the msaB region alone and compared the
phenotype of the msaB mutant with that of the msaABCR mutant. The deletion of the
msaB gene alone caused a similar decline in the transcription and production of the
capsule as observed in the msaABCR mutant (Figure 2.2a). However, importantly, the
msaB mutants showed low levels of capsule production, whereas the msaABCR mutants
showed no detectable capsule production (Figure 2.2c).
To evaluate the consequences of the lack of capsule production in the msaABCR
and msaB mutants, we examined the phenotypes associated with the capsule functions in
host cells. Several studies have shown that the production of the capsule by S. aureus
plays a role in its evasion of either phagocytosis or its elimination by components of the
host immune system (16, 18-21). Therefore, we measured the susceptibility of the
msaABCR and msaB mutants to phagocytosis by human PMNs in vitro. In both
serotypes, the deletion of the msaABCR operon and msaB led to a significant increase in
phagocytosis (Figure 2.3a). We also examined the effect of the deletion of the msaABCR
operon and msaB on bacterial clearance from heparinized whole human blood. We added
post-exponentially grown cultures of both strains and their corresponding msaABCR and
msaB deletion mutants to heparinized whole human blood that had been freshly collected
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from volunteers. The wild-type strains of both serotypes survived significantly better than
both the msaABCR and msaB mutants (Figure 2.3b). Complementation of the mutants
with a functional copy of the msaABCR operon restored their survival to levels
approaching to those of the wild type. When comparing the results of the mutation of the
msaABCR operon and the msaB region alone we noticed that even-though both mutations
lead to significant differences in clearance in both models the results of the msaB region
alone are not as significant as the whole msaABCR operon. We speculate that this is
likely due to the low levels of capsule production displayed by the msaB mutant. These
findings suggest that additional elements in the msaABCR operon, such as the three
noncoding RNAs (msaA, msaC, and msaR) play an additional role in the regulation of
capsule production. Additionally, we compared the results from both experimental
models to UAMS-1 capA::Tn mutant. We observed that the mutation of the msaABCR
operon, msaB, and capA all resulted similarly in a significant increase in clearance in
both models used. These results suggest that the deletion of the msaABCR operon and
msaB plays an important role in the bacterial resistance to phagocytosis and serum
immune factors. Due to these phenotypes being associated with capsule production (16,
18-21), we conclude that the increased susceptibility to phagocytosis and serum killing in
the msaABCR and msaB deletion mutants is likely due to the lack of capsule production.
This is supported by our finding that there was no statistically significant difference
between the msaABCR and the capA::Tn mutants in survival assays (Figure 2.3).
However, given the pleotropic effect of deletion of the msaABCR operon, we cannot rule
out factors other than the lack of capsule production in the reduced survival of the
msaABCR mutant. Indeed, we have also shown in several of our studies that the
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msaABCR operon plays a role in regulation of many virulence factors, biofilm
development, and antibiotic resistance (63-65, 67, 103). Further studies are needed to
examine the putative contribution of other factors effected by the msaABCR operon.

Figure 2.3 Phagocytic and whole blood survival assays.
Survival assays were performed using two different methods. Bacterial cells were mixed with freshly isolated human neutrophils to
measure their survival rates against phagocytosis (a). Bacterial cells were mixed with heparinized human whole blood to measure their
survival rates in the presence of complement proteins (b). Results are presented as percentages of surviving bacterial cells relative to
the control, which contained water instead of neutrophils (a) or by comparing the direct count of bacteria added to the total inoculum
with the total CFUs enumerated, corrected by any dilution factor (b). Results represent the means of three independent experiments.
Bars represent standard errors. Student’s unpaired t-test was used to compare the results of wild types to their respective mutants. The
results were displayed by asterisks using the following P value cutoffs: (NS P > 0.05, ** P ≤ 0.01, *** P ≤0.001)

2.3.2 MsaB binds to the 10-bp regulatory region within the cap promoter
Detailed analysis of the cap operon promoter identified the tentative –35 and –10
sequences and concluded that it is highly regulated (78). As discussed, to date, several
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DNA-binding proteins have been shown to directly interact with the cap promoter region,
but only one regulator, RbsR, has been shown to directly interact with the 10-bp inverted
repeat (94-98, 102). We investigated the regulatory relationship between the msaABCR
and cap operons by testing whether the putative DNA-binding protein, MsaB, interacts
with the cap promoter, using ChIP assay (Figure 2.4a). The MsaB protein bound to the
promoter region of the cap operon in both serotypes (Figure 2.4a). Previously, (78)
identified a 10-bp inverted repeat directly upstream from the promoter region, which they
proposed as a binding site for a not-yet-identified activator. We tested whether MsaB
binds specifically to this 10-bp binding domain. We synthesized a 22-nucleotide DNA
duplex containing the 10-bp inverted repeat and tested its binding to purified MsaB using
EMSA (Figure 2.4b). We observed a significant shift in the band when MsaB and the
probe containing the 10-bp inverted repeat were mixed, indicating a specific interaction
between MsaB and the 10-bp inverted repeat region (Figure 2.4b). Unlabeled competitor
DNA, was added in 10-fold molar excess as a specific competitor and was found to
reduce the formation of the protein-DNA complex. Furthermore, no retarded proteinDNA complex was detected when a random DNA probe that does not contain the 10-bp
inverted repeat was used as a control. We further tested the specificity of this binding
event by mutating one nucleotide in the 10-bp region (T to C) and showed that this
change abolished its binding to MsaB (Figure 2.4b). This confirms the previous findings
of Ouyang et al. (1999), who performed a full analysis on the individual nucleotides
within this repeat. This nucleotide was found as one of the critical nucleotides involved
the regulatory functions of the repeat and prospected to play an important role in the
binding of a putative activator. Taken together, these results show that the 10-bp inverted
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repeat is an MsaB binding site that is required for transcriptional activation of the cap
operon by MsaB.

Figure 2.4 CHIP and EMSA of MsaB binding to the cap promoter region.
(a) Chromatin immunoprecipitation (ChIP) using an anti-MsaB antibody was performed to determine if the promoter region of the cap
operon binds to MsaB from whole-cell extracts in different growth phases (early-, mid-, late-, and post-exponential phases) from two
strains that produce the two clinically relevant capsule serotypes (Mu50 for CP5 and UAMS-1 for CP8). Primers specific for the cap
promoter region were used to amplify the DNA after immunoprecipitation. Lanes are labeled as follows: “WT” represents whole-cell
extract from the wild-type strain and anti-MsaB; “Mutant” is the negative control, representing the whole-cell extract from the
msaABCR deletion mutant and anti-MsaB; “(+) Control” represents the PCR product amplified from the genomic DNA of the tested
strain. MsaB bound specifically to a 10-bp repeat region upstream from the cap promoter. (b) Map of the cap promoter region
showing the 10-bp repeat region that binds MsaB. DNA probes used in the EMSA assays are also shown. EMSA showed that purified
MsaB bound to the DNA probe containing the 10-bp repeat region. All of these results are representative of at least three independent
experiments.

2.3.3 MsaB binding to the cap promoter is dependent on nutrient availability
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The cap operon is expressed in the late- and post-exponential growth phases, but
not in the early- and mid-exponential growth phases during in vitro growing conditions.
We have shown that MsaB specifically binds to the 10-bp regulatory region upstream
from the cap promoter. Based on the time points that capsule is produced in our in vitro
analysis and the known regulatory functions of capsule production, we investigated the
role of MsaB in the temporal regulation of capsule production and how it might interact
with other regulators.
We measured the expression of MsaB in four growth phases (early-, mid-, late-,
and post-exponential) with a western analysis using an anti-MsaB antibody. We found
that MsaB was produced in all four growth phases in both Mu50 and UAMS-1 (Figure
2.5a), although the expression of MsaB decreased in the post-exponential growth phase.
Additionally, we measured the transcript level of msaB in all four of the growth phases in
both strains. The absolute values of msaB were calculated normalizing the unknown CT
values to standard values plotted on a standard curve (Figure 2.5b). We used a ChIP
analysis to examine the binding capacity of MsaB in all four growth phases and found
that MsaB binds to the cap promoter only during the late- and post-exponential growth
phases (Figure 2.4a). This indicates that despite the presence of MsaB in the early- and
mid-exponential growth phases, it is not able to bind to the cap promoter. This may be
attributable to a change in the affinity of MsaB for the 10-bp binding site or the presence
of another regulator that interferes with the binding of MsaB during the early- and midexponential growth phases. Other regulators have been shown to repress capsule
production by binding to the cap promoter. Based on the growth phase dependence
observed on capsule production we hypothesized that nutrient availability may be playing
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a part in binding of MsaB to the cap promoter region. Nutrient and metabolic sensing
regulators such as CodY and CcpE respond to nutrient levels, which change with the
depletion of nutrients and metabolic factors as the cells progress through their growth
phases. Indeed, in Bacillus subtilis, CodY was shown to have a high affinity for its
binding site under high-nutrient conditions, such as in the early-exponential growth
phase, and a low affinity under low-nutrient conditions, such as in the post-exponential
growth phase (99, 100).
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Figure 2.5 Western blot of MsaB and absolute quantification of msaB throughout
exponential growth phases.
(a) Western blot of Mu50 and UAMS-1 whole-cell lysates probed with an anti-MsaB antibody. Cells were harvested in the early-,
mid-, late-, and post-exponential phases of growth and lysed, and 25 μg of protein was loaded in each lane. These results are
representative of three independent experiments for each sample set. (b) Absolute quantification of msaB in the four growth phases.
Amplicons of msaB were converted to copies per microliter and then serially diluted and used as templates for qRT-PCR. Standard
curves were generated by plotting threshold cycle (CT) values against the log of the copy numbers (log starting quantity [SQ]). Starting
quantities of “unknown” samples were calculated by plotting the respective CT values on the standard curve. Copy numbers were
measured by raising 10 to the power of the SQ (10 SQ). These results are representative of triplicate independently treated samples.

We examined the effect of nutrient availability on the production of capsule and
on the binding of MsaB to the cap promoter region. We introduced cells into nutrient
replenished medium in late-phase of growth and allowed them to grow for two additional
hours and compared them to cells grown under normal conditions in late-phase of
growth. We observed a significant decline in the production of capsule relative to that in
cells grown under normal conditions (Figure 2.6a). We also observed similar results in
transcriptional down-regulation (-6.01 fold in Mu50; -4.74 fold in UAMS-1) of capA
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under these conditions. Additionally, we tested cells growing in nutrient-depleted
medium. We introduced cells into the nutrient-depleted medium during the early phases
of growth and allowed them to grow for two additional hours and compared them to cells
grown under normal conditions to the mid-phase of growth. We found that capsule was
produced in the nutrient-depleted growth conditions, whereas the control cells grown in
normal medium produced no capsule (Figure 2.6b). This correlated with upregulation of
transcription of capA under the same conditions (2.87 fold in Mu50; 2.57 fold in UAMS1). As a result of these findings, we used a ChIP analysis to test whether MsaB binds to
the cap promoter in these nutrient-depleted conditions. Indeed, we found that MsaB
bound to the cap promoter in the cells grown in nutrient-depleted conditions differing
from cells measured the mid-exponential growth phase under normal growing conditions
(Figure 2.6c). These results suggest that nutrient availability has a direct effect on the
ability of MsaB to bind the cap promoter and activate capsule production. We
hypothesize that either the MsaB protein is involved in sensing nutrient levels directly or
that MsaB can only bind to the cap promoter when other nutrient-dependent regulators
are not bound, which occurs when nutrient levels are low. Further studies are needed to
investigate any direct links of MsaB sensing nutrients and the possibility of an interplay
between MsaB and other nutrient-sensing regulators in controlling capsule production.
Taken together, these results show that the msaABCR operon is involved in capsule
production in response to nutrient availability.
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Figure 2.6 Total CP production and binding under altered nutrient conditions.
Total CP production was assessed in the representative CP5 and CP8 strains, including the wild types, the respective mutants, and the
controls, in nutrient-replenished medium (a) and nutrient-depleted medium (b). Samples were serially diluted as indicated on the left
and dot-blotted directly onto the membrane. The blots were processed using CP5- and CP8-specific antibodies. (c) Chromatin
immunoprecipitation (ChIP) using an anti-MsaB antibody was performed to determine whether the promoter region of the cap operon
binds to MsaB from whole-cell extract under nutrient-depleted conditions in the mid-exponential phase of growth. As in previously
described ChIP reactions, primers specific for the cap promoter region were used to amplify the DNA after immunoprecipitation.
Lanes are labeled as follows: Mu50 (nutrient-depleted) and UAMS-1 (nutrient-depleted) represent whole-cell extracts from wild-type
CP5 and CP8 strains, respectively, and anti-MsaB antibody; ΔmsaABCR Mutant, represents whole-cell extract from a msaABCR
deletion mutant and anti-MsaB antibody; (+) control, represents PCR product amplified from the genomic DNA of the tested strain.
These results are representative of three independent experiments.

2.4 Discussion and Conclusions
The capsule is a very important virulence factor in S. aureus, and facilitates its
evasion of phagocytosis during infection (19). This is particularly important during
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certain types of infection, such as bacteremia or septicemia, when the pathogen must
survive in the circulation, within the host’s blood (16, 18, 20-22). In this study, we have
demonstrated that the msaABCR operon is essential for capsule production in the two
most clinically relevant capsule serotypes of S. aureus, CP5 and CP8. Importantly, we
have shown that the regulation of the cap operon by the msaABCR operon is similar in
both serotypes. This is an important consideration because future therapeutic agents are
being developed against the capsule, and it is therefore important to understand whether
strain differences must be factored in (116-118). However, we cannot rule out possible
differences in the regulation of capsule production in other strains because we have only
tested two representative strains. Although capsule production is very important in the
survival of S. aureus during different phases of infection, very little is known about the
mechanism that regulates the cap operon. Several global regulators have been shown to
affect the production of the capsule, indicating that several environmental and host
signals must be integrated to fine-tune this process (87-93).
Previously, we have shown that the msaABCR operon is involved in virulence,
biofilm development, and antibiotic resistance (63-65, 67, 103). In this study, we found
that MsaB, encoded by the msaABCR operon, binds directly to a previously identified 10bp inverted regulatory repeat located immediately upstream from the identified cap
promoter region. We have shown that MsaB is an activator of the cap operon that binds
to the cap promoter region in the late- and post-exponential phases of growth. Since,
MsaB is produced throughout all growth phases, we hypothesize that either MsaB is not
in its active form in all these phases or that its binding site may not accessible when other
regulators are bound to this region. Our findings suggest that nutrient availability is an
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important factor in MsaB binding to this region and activating capsule production. One
possible mechanism for regulation of the cap operon by MsaB is that in early phases of
growth when nutrients and metabolic factors are high nutrient-sensing regulators (cap
repressors) such as CodY or CcpE bind to this region and block MsaB from binding and
activating cap. When nutrient levels begin to drop in later phases of growth these
repressors putatively become unbound freeing up the MsaB binding site, MsaB can then
bind to its binding site and activate transcription. Our results show that the putative
derepression by these regulators is not sufficient for the high-level transcription of the
cap operon or the production of the capsule. In the absence of MsaB, the cap operon is
expressed at the basal level and therefore the fine tuning of both regulators, repressor and
activator, are necessary for the full production of the capsule under low-nutrient
conditions. Because several global regulators have been shown to modulate the
production of the capsule, we are confident that other environmental stimuli are involved
in the repression or activation of the cap operon. It will be very interesting to investigate
how these signals are integrated with the proposed MsaB regulatory mechanism
(activation) of capsule production. Additionally, MsaB itself may be sensing nutrient
levels in an undetermined mechanism altering its ability to bind to this region.
Considering these different possibilities, we plan to test these two possible regulatory
mechanisms and to examine their relevance to pathogenesis.
The msaABCR operon regulates capsule production very tightly because the
deletion of the operon leads to undetectable levels of the capsule. We believe that this is
mainly attributable to the specific binding of the MsaB protein to the 10-bp inverted
repeat upstream from the cap promoter. This region was analyzed in detail by Ouyang et
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al., who showed that several nucleotides are essential for its binding (78). Indeed, with
respect to the prior work of Ouyang et al., the mutation of a single nucleotide (T to C) led
to the loss of binding of MsaB to this repeat region (Figure 2.4b). We chose this
particular mutation to test the specificity of MsaB binding to its target region because this
mutation is found in the epidemic USA300 lineage. The USA300 strains do not produce a
capsule even though they carry the cap operon with a sequence similar to those of Mu50
and UAMS-1, except for the T-to-C mutation in the MsaB-binding region (119, 120). We
propose that this mutation may be the main reason that USA300 strains do not produce
capsule, but without further analysis, we cannot rule out other causes. It is also unclear at
this point whether the lack of capsule production contributes to the heightened virulence
of this lineage (119, 120). Additionally, several strains that are classified as capsule
nontypeable or capsule nonproducers have also been shown to contain mutations in the
MsaB-binding region, and we also propose that these strains do not produce capsule
because MsaB cannot activate the cap operon (121). Of note, RbsU has also been found
to bind to this region. At this time, it is unknown if any interactions take place between
RbsU and MsaB in the binding to this region and we intend to investigate this further.
The deletion of the msaABCR operon led to a significant reduction in the
transcription of the cap operon, and a decline in capsule production to undetectable
levels. However, the msaB deletion mutant showed some residual capsule production. At
this point, it is unclear why we observe any residual activity because neither the
msaABCR nor the msaB mutants express MsaB. Furthermore, the msaB mutants show
reduced survival in the presence of neutrophils and whole blood relative to that of the
wild type, but not reduced to the same level as the msaABCR mutants. It is not clear
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whether the difference in the survival rates of the msaB and msaABCR deletion mutants is
significant to the relative virulence of the two strains. However, these findings suggest
that another element in the operon plays an additional role in the regulation of capsule
production. Also, it is likely that the operon and MsaB regulator has additional functions
other than the production of capsule that are involved in the survival against host immune
components and we are not ruling this out at this time. Our previous work on the
msaABCR operon showed that MsaB is the only protein-coding gene in the operon.
Therefore, we hypothesize that one of the three noncoding RNAs, msaA, msaC, or msaR,
plays a role in regards to the regulation of capsule production (65). We plan to investigate
this possibility in order to fully understand this regulatory process. This hypothesis is
further supported by the observation that the msaB mutants cannot be complemented by
the reintroduction of msaB alone but are only complemented by the reintroduction of the
whole msaABCR operon.
MsaB is predicted to be part of the cold shock protein family, carrying the DNAbinding cold shock domain, based on a protein homology analysis (122). Members of this
family have been shown to be either constitutively expressed or induced by stresses,
including nutrient starvation during the late-exponential or stationary phase of growth
(123). Additionally, MsaB also appears to contain GTP-binding regions, which may
respond to nutrient availability (124). The findings of our study suggest that nutrient
availability or metabolic sensors may play a key role in capsule production, and we
propose that MsaB is one of the factors that are directly sensitive to nutrient levels or
other signals required for capsule production. We intend to investigate this possibility in
the future. Taken together, these findings support the mechanism of an interplay between
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several regulators including the fine tuning of binding between transcriptional repressors
and the activator, MsaB, which controls the production of the capsule in response to
growth and nutrient availability.
This study will allow us to further investigate the roles of other environmental
signals involved in capsule production. We do not yet fully understand the mechanisms
involved in the expression of MsaB or how they affect capsule production under various
conditions. Studies are underway to address these issues, as well as exploring if MsaB
may have direct interactions with the other regulators that have been identified to bind to
and regulate the cap operon.
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Table 2.1 Lists of Primers used in this study.
Primers

Sequence (5’ → 3’ end)

Primer for msaABCR deletion and complement

Operon del 1

GGGGACAAGTTTGTACAAAAAAGCAGGCTGCTTTAAATCAGC
GATTAATGTTCGTTTG

(67)

Operon del 2

ATGACTGGATCCTATTAAAGACCCCTTCCATACTTCAAAAAC

(67)

Operon del 3

ATGACTGGATCCTTTCATGATGCTTGTTTAAAGTGTGGTAT

(67)

Operon del 4

GGGGACCACTTTGTACAAGAAAGCTGGGTAGTTTGGATTATCA
ATTCAATATGGCTTAGC

(67)

Comp-F1

GGGGGATCCTTTTACCACCTCATAATGTTAT

(67)

Comp-R1

CCCGAATTCAAATAAACAAAGTAATCCCCGA

(67)

Cm-F

GTTTAAGGGCCCACCTAGGTATTATCAAGATAAGAAAGAAAAG

(67)

Cm-R

CTATGACTCGAGGCCGCGGCCTTCTTCAACTAACGGGG

(67)

msaB del 1

GGGGACAAGTTTGTACAAAAAAGCAGGCTGCTTTAAATCAGCG
ATTAATGTTCGTTTG

msaB del 2

AACGTTGTTAAAGGATCCTTCTTAGATTTGAATCATTGAT

msaB del 3

CCTTGTTTCAGGATCCGAAACCTCCAAGACTAAAATTCAT

msaB del 4

GGGGACCACTTTGTACAAGAAAGCTGGGTAGTTTGGATTATCA
ATTCAATATGGCTTAGC

Primers for Real time PCR
RT gyrA F
GCCGTCAGTCTTACCTGCTC
RT gyrA R

AATAACGACACGCACACCAG

RT capE F

ACATTGGTGATGTGCGTGAT

RT capE R

TCACATGACGGCACTTGTTT

Primers for cap promoter activity
cap promoter F
ATGCATGGTACCAGTAAAAAATGCCACATAAACTTTAAGTC
cap promoter R

AGTCTAGGATCCTGTACTTTCCATTATTTACCTCCCTTAAA

Primers for ChIP
cap-ChIP F

CTACTTTAGAGTATAATTATTTTTAATTTC

cap-ChIP R

CCCTTAAAAATTTTCATTAAAATTG

Primers for recombinant MsaB
pH6HTN-msaB-F GAATGTCTAGAATGAAACAAGGTACAGTTAAATGGTTT
pH6HTN-msaB-R ATTAAGGGCCCTTATAGTTTAACAACGTTTGCAGCTT
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CHAPTER III – MSAB AND CODY INTERACT TO REGULATE
STAPHYLOCOCCUS AUREUS CAPSULE IN A NUTRIENT-DEPENDENT
MANNER
3.1 Introduction
Staphylococcus aureus is a human commensal bacterium that often
asymptomatically colonizes the anterior nares and skin of healthy individuals. However,
S. aureus is an opportunistic pathogen that can also cause life-threating infections (11,
12). The process by which the bacterium adapts from a commensal lifestyle to a
pathogenic one is linked to a plethora of regulatory loci of S. aureus (11, 12, 68, 69). The
fine-tuning of these regulatory loci is necessary for the organism to alter basic metabolic
processes and to activate an arsenal of virulence factors, such as the production of
capsular polysaccharides, which are required for successful colonization and infection
(19, 70, 71, 125). The in vitro expression of many of these virulence factors, including
both extracellular and surface associated proteins, is tightly regulated to specific phases
of growth. For instance, many surface-bound proteins (i.e., fibronectin-binding protein,
coagulase, and protein A) are expressed during the exponential phase of growth, whereas
many secreted proteins, such as extracellular proteases and capsule polysaccharide, are
predominantly expressed during the post-exponential phases of growth (71, 110, 126,
127). However, knowledge of the environmental factors or host factors encountered in
vivo that impact the regulation of expressed virulence factors remains poorly understood.
Recently, several nutrient sensing regulatory proteins have been identified as an
important “crossroad” for the switch from commensal to pathogenic states, a step that is
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essential for the establishment of an infection (70, 128-130). This nutrient-dependent
regulation is necessary for the organism to adapt to and survive during the different
nutrient-limiting or stressful conditions encountered within the host during the
colonization and infection processes. The production of the capsule polysaccharide has
been shown to be an important factor in this switch from a commensal to a pathogenic
form by aiding the ability of the pathogen to survive during infection (19, 20, 22, 23,
131). S. aureus capsule polysaccharide has been shown to have a major role in bacterial
virulence during infection by facilitating the survival of the pathogen inside the host,
primarily via acting as an antiphagocytic factor to escape phagocytic uptake (15-17). As
previously mentioned, in vitro capsule polysaccharide production is regulated in a
growth-phase dependent manner and is suppressed during the early- and mid-exponential
growth phases and activated during the late- and post-exponential growth phases (81-83,
132). However, our previous data, as well as those from other groups, suggests that, in
addition to growth phase, nutrient availability is also critical for the control of capsule
production (19, 81, 85, 86, 132).
S. aureus possesses four main capsule serotypes including CP1 and CP2 which
are known to be heavily encapsulated and serotypes CP5 and CP8 that are considered to
be micro-capsulated. However, only CP5 and CP8 are considered to be clinically
significant due to the two serotypes representing 70-80% of clinical isolates (75-77).
Capsule production is transcriptionally encoded by a single operon that contains sixteen
genes (78, 79). The genetic sequences of the operons responsible for production of CP5
and CP8 serotypes are very similar. Indeed, the serotype-specific genes are found within
the middle of the operon and are flanked by a nearly-identical common regions (80).
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Based on the similarities of the gene sequences of these two serotypes, it is thought that
the regulation of the two serotypes is also similar (80, 132). Indeed, the promoter regions
of both serotype 5 and 8 operons are located directly upstream from the capA ORF and
share sequences that are nearly identical. Detailed analysis of the cap operon promoter
region indicated that it is highly regulated (78). Generally, the activity of the cap
promoter correlates with capsule polysaccharide synthesis, suggesting that regulation
predominately occurs at the level of transcription (106, 132, 133). Several regulatory
proteins have been shown to bind to the cap operon promoter region, increasing the
regulatory complexity of this region. These proteins include the two-component systems
AirSR and KdpDE, and the nutrient or stress sensing regulatory proteins CcpE, CodY,
RbsR, SpoVG, and MsaB (94-98, 102, 132). The complexity of this region results in
capsule polysaccharide being tightly regulated in a growth-phase dependent manner,
where it is suppressed during the early- and mid-exponential growth phases and activated
during the late-and post-exponential growth phases (81-83, 132).
In our previous studies, we have shown that deletion of msaABCR operon and/or
msaB significantly reduced cap-transcription as well as the production of capsule (132).
We have also observed that when we delete msaB, it can only be complemented by the
complete msaABCR operon, thus suggesting that the intact msaABCR operon is needed
for the expression and/or function of msaB (unpublished data). In addition, we have
shown that the MsaB protein, of the msaABCR operon, binds a 10-bp regulatory repeat
located directly upstream of the cap promoter and activates capsule production (132).
We found that MsaB only binds to the cap promoter region during the late- and postexponential phases of growth under nutrient-rich growth conditions, even though MsaB is
43

present throughout all growth phases. However, when the nutrient concentrations were
altered, the binding ability of MsaB changed, which led to observable changes in the
expression of the cap transcript as well as the production of capsule polysaccharide. This
indicates that nutrients are important for the regulatory interaction of MsaB binding to
and activating the cap promoter (132). This led us to hypothesize that the binding ability
of MsaB may be altered by changes in nutrient concentrations or that the MsaB binding
site may be masked by other regulatory proteins under these conditions. Two nutrientsensing regulatory proteins, CodY and CcpE (catabolite control protein E), have been
shown to bind to the cap promoter region as repressors of cap production (95, 97). In
this study, we show that complex regulatory interactions are present between MsaB and
the other nutrient dependent cap regulators CodY and CcpE. We observed that nutrient
concentrations influence the binding capability of these regulators within the cap
promoter region. Interestingly, we observed that not only are these regulators controlling
the cap promoter region, but the MsaB, CodY, and CcpE regulators appear to be
responsible for the transcriptional regulatory control of each other in complex and
incoherent feed-forward loops. We found that mutation of any of these regulators
significantly altered the transcription of the other regulators as well as the cap transcript,
further demonstrating the tight regulatory control of cap. The interactions between these
putative global regulatory proteins seems to lie at the “crossroad” between basic
metabolic processes and the coordinated control of the production of virulence factors
required for the bacterium to establish infection.
3.2 Methods
3.2.1 Bacterial strains and growth conditions
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For this study, we used UAMS-1 as a representative strain for the clinically
significant capsule serotype CP8, as was done is our previous study (132). The
restriction-deficient laboratory S. aureus strain RN4220 and the Escherichia coli strain
DH5 were used to move plasmid constructs into the strains of choice through
transformation and phage transduction as described previously (65, 67, 107). S. aureus
strains were routinely grown in tryptic soy agar (TSA) or tryptic soy broth (TSB) as
appropriate, unless otherwise noted in the experiments with altered nutrient conditions in
which the strains were grown in chemically defined media (CDM), as described
previously, with specific nutrients added as outlined per individual experiment (101).
When required, either erythromycin (10 g mL–1) or chloramphenicol (10 g mL–1) was
added to TSB or TSA for selection. The E. coli strain was grown in Luria–Bertani (LB)
medium, with ampicillin added (100 g mL–1) when required for selection.
3.2.2 Generation of transposon mutants and complementation
The codY and ccpE mutants were generated by insertion of a transposon in the
codY or ccpE ORFs. Briefly, the strains NE1555 (SAUSA300_1148) “CodY” and
NE1560 (SAUSA300_0658) “CcpE” were obtained from the Network on Antimicrobial
Resistance in Staphylococcus aureus (NARSA) collection (BEI Resources, Manassas
VA). These strains contain the bursa aurealis mariner-based erythromycin resistanceexpression transposon within the encoding codY or ccpE region, respectively. The
mutations were mobilized by generalized transduction using bacteriophage Φ11 (63, 67,
132) into wild-type UAMS-1. The introduction of codY::Tn and ccpE::Tn mutations were
verified by PCR, followed by sequencing and phenotypic assays (95, 97, 101, 134, 135).
For trans-complementation, the codY or ccpE ORFs having 6X encoded histidine residues
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at the 5’ end of the ORFs were cloned into the pCN34 low-copy vector with the
modification of changing the kanamycin selectable marker to a chloramphenicol resistant
marker as described previously (67, 108, 132). These complementation vectors were used
in the qRT-PCR experiments and phenotypic assays. In addition, we used these
complementation vectors with the 5’ 6X histidine residues (6XHIS-codY or 6XHIS-ccpE)
to perform the chromatin immunoprecipitation (ChIP) assay.
3.2.3 RNA extraction, reverse transcription, and qRT-PCR
The expression of capE and msaB was measured by qRT-PCR in wild-type, the
corresponding mutants, and complemented strains. Briefly, an aliquot of an overnight
culture was normalized to an optical density of 600 nm (OD600) to 0.05 and then grown to
the corresponding growth phase. After the cells had grown to the appropriate growth
phase (early-, mid-, late-, or post-exponential phase), cells were pelleted by
centrifugation at 10,000 x g, treated with the RNAprotect™ Bacteria Reagent (Qiagen,
Valencia CA), and stored at –80°C until analysis. For the analysis, the samples were
thawed on ice and total RNA was extracted as previously described (65, 67, 132). Next,
qRT-PCR was performed using the appropriate primers (Table 3.4) and the relative fold
change in gene expression was calculated using gyrA as an internal control for
normalization (65, 67, 110, 132).
3.2.4 Absolute quantification of the codY and ccpE transcript
Absolute quantification of the codY and ccpE transcripts was performed by the
method previously described by others and our previous work (132, 136). The codY and
ccpE genes were amplified from chromosomal DNA using primers external to the
primers used for qRT-PCR. The PCR amplicons were purified and their concentrations
46

were measured using a Nanodrop spectrophotometer (Thermo Scientific). The
corresponding concentrations were converted to copies per microliter using a previously
described method (112). Tenfold serial dilutions (10-1 to 10-8) of these amplicons were
used as templates for qRT-PCR. Standard curves were generated by plotting threshold
cycle (CT) values against the log of the copy numbers (log starting quantity [SQ]).
Starting quantities of “unknown” wild-type samples (early-, mid-, late-, and postexponential cDNA of UAMS-1) were calculated by plotting the respective CT values on
the standard curve. Copy numbers were measured by 10SQ. The respective copy numbers
of codY or ccpE were normalized to those of gyrA and plotted against the standard curve
to obtain the absolute transcript copy numbers of codY or ccpE. The experiment was
repeated in triplicate in independent assays.
3.2.5 In vitro capsule production assay
Total capsule production was determined using a dot-blotting method described
previously (88), with the following modifications described in our previous work (132).
In brief, 2 mL of an 18-h culture, adjusted to an OD660 of 5.0, was pelleted and
resuspended in 100 µL of phosphate-buffered saline (PBS). The suspension was
sequentially treated with the following enzymes at 37°C: lysostaphin (100 µg mL–1) for
15 min, DNase I (300 U mL–1) for 15 min, and proteinase K (100 µg mL–1) for 1 h. The
proteinase K was subsequently inactivated by heating at 75°C for 10 min. The crude
capsule preparations were serially diluted and assayed by immunoblotting on a
membrane using a CP8 specific antibody as described previously (88, 132).
3.2.6 Expression and purification of MsaB protein
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The msaB open reading frame (SAV1402) of S. aureus strain UAMS-1 was
synthesized and inserted into the pD861 plasmid by a commercial company (DNA2.0,
USA). The Escherichia coli strain BL21(DE3) was then transformed with the resulting
plasmid, pD861-msaB, and the transformants were selected for on LB agar plates
containing kanamycin. Next, LB broth (1 L) containing kanamycin (50 μg mL–1) was
inoculated with an overnight culture (10 mL) of a positive colony. Protein expression was
induced by the addition of L-rhamnose at a final concentration of 5 mM. The cells were
pelleted 4 h after induction and resuspended in PBS (pH 7.4) with a protease inhibitor
cocktail, and then were lysed by sonication (QSonica 500, Newtown, CT). The cell lysate
was centrifuged at 10,000  g for 30 min to remove the cell debris. The His-MsaB tagged
protein was then purified from the cleared lysate with a nickel column (HisPur™ NiNTA Resin; Thermo Scientific, Rockford, IL). The tagged protein was then cleaved with
the Tobacco etch virus (TEV) protease (ProTEV Plus; Promega Corporation) to remove
the 6X-His tag. The cleaved protein band was excised from the polyacrylamide gel and
identified via mass spectrometry by a commercial company (MS Bioworks, Ann Arbor
MI). The MsaB protein was purified from the tag via reversed-phase HPLC. After the
removal of acetonitrile by vacuum centrifugation, the protein was dissolved in PBS (pH
7.4) and stored for future use.
3.2.7 Chromatin immunoprecipitation (ChIP) assays
The ChIP assay was performed as previously described (114) with minor
modifications as outlined in our previous work (132). Briefly, S. aureus cells were
grown to the growth phase required for a given experiment and were treated with 1%
formaldehyde and 10 nM sodium phosphate to facilitate the cross-linking of the MsaB,
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6XHis-CodY or 6XHis-CcpE proteins to their target binding sites. After 20 min, the
cross-linking reaction was quenched by the addition of 0.1 volume of 3 M glycine. The
cultures were subsequently washed with an equal volume of 100 mM phosphate buffer
and pelleted by centrifugation to remove the excess formaldehyde. The cells were then
resuspended in 750 µL of IP buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM
EDTA, 1 mM phenylmethylsulfonyl fluoride, 5% glycerol, and 1% Triton X-100) and
lysed by bead beating. The cell debris was removed by centrifugation and the lysate was
moved into a new tube. The cell lysates were then diluted with an additional 750 µL of IP
buffer and the cellular DNA was sheared to a size of approximately 500 bp by further
bead beating. After centrifugation at 10,000 x g, the supernatant was diluted with an
additional 1 mL of IP buffer. To 500 µL of the cleared lysate, anti-MsaB or ChIP grade
anti-HIS (Abcam, Cambridge, UK) antibodies (diluted 1:1000) were added and incubated
with continuous mixing at room temperature for 2 h. The antigen-antibody mixture was
then added to prewashed protein-G-coupled magnetic beads (ThermoFisher Scientific
Pierce) and incubated under ambient conditions with continuous mixing for 1 h. The
antigen-antibody-bead complexes were collected with a magnetic stand and washed, after
which the antigen-antibody complexes were eluted followed by decoupling of the
antigen-antibody complexes. After the decoupling step, the DNA was extracted using the
phenol-chloroform extraction method followed by ethanol precipitation as previously
described (132). The DNA was used as template to detect the MsaB, CodY, or CcpE
bound promoter sequences by PCR amplification using promoter-specific primers. The
msaABCR operon mutant or the codY and ccpE mutants without the 6XHIS-
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complementation constructs were used as internal negative controls to demonstrate that
the antibodies specifically enriched the tested promoter region.
3.2.8 Electrophoretic mobility shift assay (EMSA)
DNA fragments containing the promoter regions of the codY 1.4 kb ORF, the
xerC-clpQY-codY operon, and ccpE were amplified by PCR to produce double-stranded
DNA fragments. These fragments were amplified using primers that incorporated a 5’
biotin tag to each DNA fragment. Additionally, unlabeled (cold) probes of the same
amplicons were produced by PCR in a similar manner using primers that did not
incorporate the 5’ biotin tag. These PCR fragments were then purified using a PCR &
DNA cleanup kit (NEB, USA) according to manufacturer’s protocol. After purification,
the biotinylated or cold double stranded DNA concentrations were measured using a
Nanodrop spectrophotometer (Thermo Scientific) and were used as EMSA DNA probes.
The shift assays were performed with the LightShift Chemiluminescent EMSA Kit
(Pierce, USA) according to the manufacturer’s protocol. Briefly, the 5-biotinylated DNA
probes were incubated with increasing concentrations of purified MsaB protein for 20
min at room temperature in a 20 µL volume containing reaction buffer (1  binding
buffer, 2.5% glycerol, 5 mM MgCl2, 50 ng mL–1 poly dI-dC, and 0.05% NP-40). The
cold DNA probes were used in at least 10-molar excess as a specific competitive binding
control in the reactions. The samples were subjected to electrophoresis in a native 6.0%
polyacrylamide gel. The proteins in the gel were then visualized using the detection
module supplied with the kit according to the manufacturer’s protocol and imaged with
the ChemiDoc™ System (BioRad) to assess the presence of shifted bands.
3.2.9 Altered nutrient experiments
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To observe the effect of nutrient limitation on the production of capsule, as well
as the regulatory effects of MsaB and CodY, we used a (CDM) as previously described
(101). Briefly, overnight cultures grown in TSB were diluted 1:10 in fresh, prewarmed
CDM and then were incubated for an additional 2 h. Subsequently, the cells were
normalized to a OD600 of 0.05 in fresh, prewarmed CDM for use as the starter culture.
These cells were compared to cells grown under nutrient-rich growth conditions (TSB) in
the representative and corresponding phases of growth. Additionally, we compared cells
grown in CDM with BCAAs or cells grown in CDM with BCAAs followed by their
introduction into CDM without BCAAs (valine, leucine, and isoleucine; Sigma-Aldrich,
USA). Briefly, exponential cultures in the representative growth phase, growing in CDM
with BCAAs, were collected by centrifugation at 10,000 x g and resuspended in CDM
without BCAAs. These cells were further incubated at 37°C with shaking (220 rpm) for
an additional 30 min, after which they were collected by centrifugation. These CDM
without BCAAs-treated cells were compared to cells grown similarly in CDM with
BCAAs. Using these different nutrient conditions, we tested the capsule phenotype as
well as the binding profile of MsaB and CodY under different nutrient conditions.
Additionally, we observed how the change in nutrients plays a role in the regulatory
interactions between these two regulators with respect to cap.
3.3 Results
3.3.1 MsaB, CodY, and CcpE coordinately regulate transcription of the cap
promoter activity and therefore capsule production
We have previously shown that MsaB of the msaABCR operon, is a DNA-binding
transcriptional activator of capsule production in S. aureus. We observed that MsaB
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activates the cap promoter region in the late- and post-exponential growth phases under
nutrient-rich (TSB) growth conditions. However, under nutrient-limited conditions,
MsaB is able to bind to the cap promoter region in the early phases of growth (132).
Additionally, numerous other regulatory proteins have been shown to bind to this region
and regulate capsule production under different conditions, including AirS, RbsR,
SpoVG, KdpE, CodY, and CcpE (94-98, 102). In this study, we further investigated the
nutrient-dependent regulation of capsule production by MsaB. We examined interactions
between these DNA-binding cap regulators and MsaB. We tested if mutating the
msaABCR operon had any regulatory effect on the known DNA-binding regulators of
cap, including AirSR, CcpE, CodY, KdpDE, RbsR, and SpoVG in the mid-exponential
growth phase. Interestingly, we found that the msaABCR operon mutation resulted in a
change in the transcriptional regulation of both nutrient responsive regulators ccpE
(upregulated) and codY (downregulated). However, no regulatory changes were observed
for any of the other regulators of cap, suggesting that no direct regulatory interactions
occur between msaABCR and these regulators (Table 3.1). Thus, for this study, we
focused on the nutrient-dependent regulators CodY and CcpE to determine how they may
interact with MsaB to coordinately control cap and ultimately capsule production in
response to nutrient stimuli.
Table 3.1 Expression of cap-binding genes in the msaABCR mutant relative to the wildtype strain.
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To examine the nutrient dependent regulatory mechanism of the cap operon, we
generated the individual and double mutants codY, ccpE, codY/msaABCR, and
ccpE/msaABCR. We compared the cap transcript, as well as total capsule production of
these mutants, to the msaABCR deletion mutant, the wild-type UAMS-1, and the
msaABCR complementation strain. We found that individual deletion of msaABCR,
codY, or ccpE results in a downregulation of cap transcription in the post-exponential
growth phase (by -23-fold, -4-fold, and -10-fold respectively; Table 3.2).
Table 3.2 Expression of capE in mutants relative to the wild-type strain.

This confirmed that all three regulators contribute to the transcription of the cap
operon. Deletion of the msaABCR operon had the highest effect on cap transcription.
This confirms our previous finding that deletion of the msaABCR operon significantly
decreased cap gene expression, resulting in capsule production being abolished (132).
Even though mutation of codY decreased cap transcription, we observed a significant
increase in capsule production in the post-exponential growth phase when capsule is
maximally produced, thus confirming the role of CodY as a repressor of capsule
production (Figure. 3.1A). These results suggest that CodY negatively regulates capsule
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production at the post-transcriptional level. Additionally, we compared the capsule
production phenotype of the double mutant to the individual codY and msaABCR
mutants. We observed that the double mutation resulted in capsule production being
undetectable (Figure. 3.1A). This indicated that in the absence of both the CodY
repressor and the MsaB activator, capsule is not produced. Taken together, these results
further support our previous finding that activation of cap by MsaB is essential for
capsule production.
As mentioned above, we found that mutation of ccpE resulted in a significant
downregulation of cap transcription, suggesting that CcpE possibly functions as an
activator of cap (Table 3.2). The mutation of ccpE alone resulted in a significant
decrease in total capsule production compared to the wild-type strain, although there
were still detectable levels of capsule (Figure. 3.1B). Additionally, we compared the
capsule production phenotype of the double mutant to the individual ccpE and msaABCR
mutants to confirm their roles in capsule production. Interestingly, we observed that in
the double ccpE/msaABCR mutant, capsule production was detectable at levels similar to
the ccpE mutant alone (Figure. 3.1B). These results suggested that ccpE may be epistatic
to msaB. Importantly, this is the first evidence of any detectable level of capsule
production in any of the msaABCR individual or double mutants. These findings suggest
that the double mutation of ccpE/msaABCR likely affects other unknown cap regulators,
resulting in the observed basal level of capsule production. However, further experiments
are needed to investigate this possibility.
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Figure 3.1 Total capsule production by in the wild-type UAMS-1 strains and in the
msaABCR, codY (A), and ccpE (B) mutants.
Capsule production was assessed in the wild-type UAMS-1 strain and in the msaABCR, codY (A), and ccpE (B) mutants, along with
the indicated double mutants. Samples were serially diluted as indicated on the left and dot-blotted directly onto the membrane. The
blots were processed using CP-specific antibodies. The results are representative of three independent experiments for each sample
set.

3.3.2 MsaB directly controls transcription of both codY and ccpE
To acquire a more comprehensive understanding of the observed coordinated
regulation between MsaB, CodY, and CcpE with respect to the regulation of cap, we
tested if the mutation of the msaABCR operon had a regulatory effect on codY or ccpE
transcription. First, we compared the absolute transcript level of codY in the msaABCR
deletion mutant to that of the wild-type UAMS-1 and the msaABCR complementation
strains. We found that the deletion of the msaABCR operon resulted in a significant down
regulation of codY in the late- and post-exponential growth phases (Figure. 3.2A).
Importantly, this correlates with the regulation of cap (repression and activation) by these
two regulators. In early phases of growth, when nutrients are high, CodY binds to and
represses the cap promoter. Conversely, in nutrient-rich growth conditions (TSB), MsaB
only binds to and activates cap transcription in the late- and post-exponential growth
phases or when nutrient availability becomes limited. These results suggest that in the
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later phases of growth (late- and post-exponential), MsaB not only binds to the cap
promoter to activate capsule production but also reduces the transcription of the cap
repressor, CodY.
To determine if MsaB regulates codY directly, we tested if MsaB directly binds to
the codY promoter using a chromatin immunoprecipitation (ChIP) assay. Briefly, codY
has two putative promoter regions: one promotes the expression of the xerC-clpQY-codY
operon and the other promotes the expression of a 1.4 kb product that contains the codY
ORF, the latter of which is responsible for producing the codY transcript alone (101). We
tested for MsaB binding to both putative promoter regions. Interestingly, we found that
MsaB binds to both putative promoters during late- and post-exponential growth phases,
but not during early- or mid-exponential growth phases (Figure. 3.2B). Additionally, to
confirm the binding of MsaB to the codY promoters, we used an electrophoretic mobility
shift assay (EMSA) to determine if purified MsaB could bind to biotinylated DNA probes
specific for the codY promoters. We observed a significant band shift when MsaB was
mixed with either codY promoter probe, indicating specific interactions between MsaB
and the promoter regions for both the xerC-clpQY-codY operon and the 1.4 kb codY
promoter (Figure. 3.2C). To confirm the binding specificity of the protein-DNA
interactions, unlabeled (cold) competitor DNA was added in 10-fold molar excess as a
specific competitor. The addition of this cold DNA was found to reduce the formation of
the protein-DNA complex. Taken together, these results show that MsaB directly
regulates both the xerC-clpQY-codY operon and the 1.4 kb transcript containing the codY
ORF in a growth-phase dependent manner. These results suggest that not only can MsaB
bind to and activate cap in the late- and post-exponential phases of growth, but that it also
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regulates the cap repressor CodY in a growth-dependent manner. The results of this
experiment show that MsaB has very tight and multidimensional regulation of the cap
promoter.

Figure 3.2 msaABCR regulates codY in a growth phase-dependent manner.
Amplicons of codY were converted to copies per microliter and then serially diluted and used as templates for qRT-PCR. Standard
curves were generated by plotting threshold cycle (CT) values against the log of the copy numbers (log starting quantity [SQ]).
Starting quantities of “unknown” samples were calculated by plotting the respective CT values on the standard curve. Copy numbers
were measured by raising 10 to the power of the SQ (10 SQ). Bars represent standard errors. Student’s unpaired t-test was used to
compare the results of between the wild-type and mutant strains. The significance of the results are indicated by asterisks using the
following P value cutoffs: NS P > 0.05, ** P ≤ 0.01, *** P ≤0.001. (B) Chromatin immunoprecipitation (ChIP) using an anti-MsaB
antibody was performed to determine if the putative promoter regions of codY bound to MsaB from whole-cell extracts during
different growth phases (early-, mid-, late-, and post-exponential phases). Primers specific for the putative codY promoter regions
were used to amplify the DNA after immunoprecipitation. Lanes are labeled as follows: “WT” represents whole-cell extract from the
wild-type strain and anti-MsaB; “Mutant” is the negative control, representing the whole-cell extract from the msaABCR deletion
mutant and anti-MsaB; “(+) Control” represents the PCR product amplified from the genomic DNA of UAMS-1. (C) EMSA showed
that purified MsaB bound to the DNA probe containing the codY 1.4 kb and the codY operon promoter regions. These results are
representative of three independently treated samples.

To investigate the regulatory control by msaABCR operon on CcpE, we compared
the absolute transcript level of ccpE in the msaABCR deletion mutant to the wild-type
57

UAMS-1 and the msaABCR complementation strains. We found that the deletion of the
msaABCR operon resulted in a significant upregulation of ccpE transcripts during all
growth phases of S. aureus strain UAMS-1 (Figure. 3.3A). CcpE has also been shown to
regulate capsule production in S. aureus. However, there have been contradicting reports
on the role or mechanism of this regulation. Ding and colleagues described ccpE as a
direct binder of the cap operon, having a repressor role (97). Conversely, ccpE has also
been described as promoting capsule formation in S. aureus (Hartmann et al., 2014).
However, this regulation was found to be non-direct, as it was observed that ccpE did not
bind cap (134). In our study, we found the ccpE mutant exhibited a decrease in cap
transcript as well as total capsule production, suggesting that CcpE is an activator of cap
transcription and capsule production.
To determine if MsaB directly regulates ccpE to induce the strong regulatory
effect observed by the mutation of the msaABCR operon in UAMS-1, we tested if MsaB
could bind to a putative promoter region upstream of the ccpE ORF using ChIP. We
observed that MsaB bound to the putative promoter region of ccpE during all phases of
growth (Figure. 3.3B). To confirm the binding of MsaB to the ccpE promoter, we used
EMSA to determine if purified MsaB bound to a biotinylated DNA probe specific for the
ccpE promoter. We observed a significant shift in the band when MsaB and the ccpE
promoter probe were mixed, indicating specific interactions between MsaB and the ccpE
promoter region (Figure. 3.3C). To confirm the binding specificity of the protein-DNA
interactions, cold competitor DNA was added in 10-fold molar excess as a specific
competitor. The addition of this cold DNA was found to reduce the formation of the
protein-DNA complex. These results suggest that MsaB directly regulates ccpE as a
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strong repressor of ccpE transcription. Taken together, these results suggest that MsaB
has an important role in regulating CodY and CcpE, which in turn is involved in the
overall nutrient-dependent regulation of cap transcription and capsule production in S.
aureus.

Figure 3.3 msaABCR regulates ccpE during all phases of growth.
Absolute quantification of ccpE in the four growth phases. Amplicons of ccpE were converted to copies per microliter and then
serially diluted and used as templates for qRT-PCR. Standard curves were generated by plotting threshold cycle (CT) values against
the log of the copy numbers (log starting quantity [SQ]). Starting quantities of “unknown” samples were calculated by plotting the
SQ

respective CT values on the standard curve. Copy numbers were measured by raising 10 to the power of the SQ (10 ). Bars represent
standard errors. Student’s unpaired t-test was used to compare the results of wild types to their respective mutants. The significance of
the results is indicated by asterisks using the following P value cutoffs: NS P > 0.05, ** P ≤ 0.01, *** P ≤0.001. (B) Chromatin
immunoprecipitation (ChIP) using an anti-MsaB antibody was performed to determine if the putative promoter region of ccpE bound
to MsaB from whole-cell extracts during different growth phases (early-, mid-, late-, and post-exponential phases). Primers specific
for the putative ccpE promoter region were used to amplify the DNA after immunoprecipitation. Lanes are labeled as follows: “WT”
represents whole-cell extract from the wild-type strain and anti-MsaB; “Mutant” is the negative control, representing the whole-cell
extract from the msaABCR deletion mutant and anti-MsaB; “(+) Control” represents the PCR product amplified from the genomic
DNA of UAMS-1. (C) EMSA showed that purified MsaB bound to the DNA probe containing the ccpE promoter region. The results
are representative of three independently treated samples.
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3.3.3 CodY and CcpE both regulate msaB transcription and/or MsaB DNA-binding
ability
In an effort to gain a comprehensive understanding of the regulatory interactions
between MsaB, CodY, and CcpE and determine how they regulate the cap transcript and
ultimately capsule production, we also tested if either the codY or ccpE mutant had any
regulatory impact on MsaB. First, the transcription of msaB in the codY or ccpE mutant
was measured during all phases of growth using qRT-PCR. Interestingly, we found that
the mutation of either codY or ccpE significantly decreased msaB expression (Table 3.3).
This was particularly evident in the early-, late-, and post-exponential phases of growth,
with little effect observed in the mid-exponential growth phase. We observed that the
mutation of either gene (codY or ccpE) had the greatest regulatory effect on the amount
of msaB transcript produced during the late- and post-exponential phases of growth.
Importantly, this is when the regulatory activity of MsaB is the most evident, as it
specifically activates cap transcription during these growth phases. These results suggest
that complex regulatory interactions occur between MsaB, CodY, and CcpE and that
these regulatory interactions are necessary for the tight control of capsule production.
Table 3.3 Expression of msaB in mutants relative to the wild-type strain.
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To investigate the putative nutrient dependent binding of CodY or CcpE to the
cap promoter, we used 5’ histidine labeled constructs for complementation assays (5’
6XHIS-codY or 5’ 6XHIS-ccpE, respectively). These constructs were transformed into
the codY or ccpE mutants for trans-complementation, respectively, and were used to
measure the binding of CodY or CcpE via the ChIP assay. Using these constructs, we
observed that under nutrient-rich conditions, CodY bound to the cap promoter during the
early-, mid-, and late-exponential growth phases, but not during the post-exponential
growth phase (Figure. 3.4A), consistent with other studies that have examined CodY
regulatory activity (95, 129, 137). We have previously observed that under nutrient-rich
conditions (TSB), MsaB binds to and activates the cap promoter during late- and postexponential growth phases, but not during early- or mid-exponential phases. These
observations suggest that when CodY is bound to the cap promoter under nutrient-rich
conditions during early-, mid-, and late-exponential phases, MsaB cannot bind to the cap
promoter. Additionally, we also observed that if we altered nutrient concentrations in the
medium, the MsaB binding ability during these phases was altered, suggesting that a
nutrient-dependent interaction is present (132).
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Figure 3.4 Chromatin immunoprecipitation measuring codY and ccpE binding to the cap
promoter.
(ChIP) using an anti-HIS antibody was performed to determine if the cap promoter region bound to (A) CodY or (B) CcpE from
whole-cell extracts during different growth phases (early-, mid-, late-, and post-exponential phases). The 6XHis-codY and 6XHis-ccpE
complement vectors were used to complement codY or ccpE in the respective individual mutants as well as the codY/msaABCR or
ccpE/msaABCR double mutant strains. Primers specific for the cap promoter regions were used to amplify the DNA after
immunoprecipitation. Lanes are labeled as follows: “WT” is a negative control, representing whole-cell extract from the wild-type
strain and anti-HIS; “ΔcodY or ΔccpE” indicate the negative controls, representing the whole-cell extracts from either the codY or
ccpE deletion mutant and anti-HIS; “ΔcodY/ΔmsaABCR or ΔccpE/ΔmsaABCR” indicate a negative controls, representing whole-cell
extracts from either the codY/msaABCR or ccpE/msaABCR double mutants and anti-HIS; “codY or ccpE 6XHis-complement”
represents whole-cell extracts from the codY or ccpE mutants complemented with 6XHis-codY or 6XHis-ccpE and anti-HIS;
“ΔcodY/ΔmsaABCR or ΔccpE/ΔmsaABCR 6XHis-complement” represents whole-cell extracts from the codY/ msaABCR or ccpE/
msaABCR double mutants complemented with 6XHis-codY or 6XHis-ccpE and anti-HIS; “(+) Control” represents the PCR product
amplified from the genomic DNA of UAMS-1. The results are representative of triplicate independently treated samples.

To determine if CodY binding alters MsaB binding to the cap promoter in a
growth phase dependent manner, we studied MsaB binding activity in the codY mutant.
We used ChIP to determine if the mutation of codY alters MsaB binding under these
nutrient-rich growing conditions. Interestingly, we found that when codY is mutated,
MsaB binds to the cap promoter during all phases of growth, including the early- and
mid-exponential phases (Figure. 3.5A). Next, we tested if this observed MsaB binding in
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the codY mutant directly led to capsule production. We observed detectable amounts of
capsule in the codY mutant during both the early- and mid-exponential growth phases
(Figure. 3.5B and C). These results suggest that, through an undetermined mechanism,
the binding of CodY to the cap promoter inhibits or blocks MsaB binding to cap.
However, when CodY is not bound or is not present (mutation), MsaB can directly bind
to and activate cap, leading to capsule production.
Interestingly, we found no evidence of CcpE binding to the cap promoter region
during any phase of growth (Figure. 3.4B). This is consistent with previous studies,
which found no evidence of CcpE binding to the cap promoter (134). Additionally,
mutation of ccpE did not appear to have any effect on the ability of MsaB to bind to the
cap promoter (Figure. 3.5A). These results suggest that CcpE regulates cap indirectly
through an undetermined mechanism and that CcpE does not have any effect on MsaB
binding to cap promoter.
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Figure 3.5 CodY alters MsaB binding ability during the early/mid-exponential growth
phases and capsule is detectable in early- and mid-exponential phases in codY mutants.
(ChIP) using an anti-MsaB antibody was performed to determine if the mutation of codY or ccpE alters the binding of the cap
promoter region to MsaB from whole-cell extracts in different growth phases (early-, mid-, late-, and post-exponential phases)
compared to the wild-type UAMS-1 strain. Primers specific for the cap promoter regions were used to amplify the DNA after
immunoprecipitation. Lanes are labeled as follows: “WT” represents whole-cell extract from the wild-type strain and anti-MsaB;
“ΔmsaABCR” is the negative control, representing the whole-cell extract from the msaABCR deletion mutant and anti-MsaB; “ΔcodY”
represents whole-cell extract from the codY mutant and anti-MsaB; “ΔccpE” represents whole-cell extract from the ccpE mutant and
anti-MsaB; “(+) Control” represents the PCR product amplified from the genomic DNA of UAMS-1. Total CP production was
assessed in the wild-type UAMS-1 strain and in the msaABCR, codY, and msaABCR/codY mutants during (B) early-exponential and
(C) mid-exponential growth. Samples were serially diluted as indicated on the left and dot-blotted directly onto the membrane. The
blots were processed using CP-specific antibodies. The results are representative of triplicate independently treated samples.

3.3.4 MsaB and CodY interact with the cap promoter region in a nutrientdependent manner
Capsule production has been shown to be largely regulated by environmental
nutrient conditions. With respect to the regulatory function of CodY, when nutrients are
high capsule production is repressed by CodY binding to the cap promoter. However,
when nutrient concentrations begin to decline, CodY undergoes a conformational change
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that results in CodY not binding to its DNA targets (138, 139). Capsule is then produced
by MsaB binding to and activating the cap promoter under these nutrient-limited
conditions. Moreover, CodY senses nutrient availability, specifically GTP and BCAAs,
for its regulatory function (99, 100). Previously, we used the prediction tool NsitePred to
analyze the MsaB sequence and found that MsaB contains a predicted nutrient-sensing
domain for nucleotides, including GTP, ADP, and AMP (124). To explore how the
interactions between MsaB, CodY, and the cap promoter may be mediated by nutrients,
we used a nutrient-limited medium (CDM) to determine how codY, msaB, and ultimately
cap is affected by the presence or absence of BCAAs. We found that by shifting cells
from growth in CDM with BCAAs to growth in CDM without BCAAs resulted in the
upregulation of cap in the wild-type strain (3.69-fold), resulting in more total capsule
production. Under the same conditions in the wild-type strain, the msaB transcript was
upregulated (3.47-fold), but the codY or ccpE transcript were both unaltered (Figure. 3.6).
These results suggest that the bacterium senses this nutrient limitation and increases
transcription of msaB, which in turn increases cap as a response to the nutrient-depleted
conditions. The mechanism for this process is still unknown.
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Figure 3.6 qRT-PCR normalized fold change.
Representative fold changes of capE, msaB, codY, and, ccpE in mid-exponential growth phase cells grown in a chemically defined
medium (CDM) with no branched chain amino acids compared to growth in complete chemically defined medium in the wild type
UAMS-1 strain. The results are representative of at least three independent experiments for each sample set.

Previous studies have shown that BCAA concentrations control CodY binding
affinity to its targets (138-140). Using CDM we tested how the presence or absence of
BCAAs affects CodY binding activity to the cap promoter. We found that under nutrient
limitation, CodY was bound to the cap promoter during early- and mid-exponential, but
not late- or post-exponential growth phases in CDM with BCAA. However, in cells
shifted from CDM with BCAA to CDM without BCAAs, CodY did not bind to the cap
promoter during any phase of growth (Figure. 3.7). Taken together, these results suggest
that CodY responds directly to the availability of BCAAs via its binding ability and
regulatory control of cap.
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Figure 3.7 Chromatin immunoprecipitation assay of CodY binding.
(ChIP) was performed using an anti-HIS antibody was performed to determine if the cap promoter region binds to CodY from wholecell extracts grown under nutrient-depleted conditions (CDM with BCAAs vs CDM without BCAAs) in different growth phases
(early-, mid-, late-, and post-exponential phases).

As a result of this CodY nutrient-dependent binding, we hypothesized that the
MsaB binding ability may be altered by the binding of CodY under different nutrient
conditions. Additionally, we used CDM with BCAAs and CDM without BCAAs to
determine if the cap promoter binding ability of MsaB during the mid-exponential phase
of growth is dependent on CodY binding. Surprisingly, the binding activity of CodY in
presence or absence of BCAAs did not seem to have any effect on the binding ability of
MsaB to cap under these nutrient-limited conditions (Figure. 3.8A). This suggests that
the binding ability of MsaB to cap is not dependent on BCAAs or the CodY binding
activity alone. Additionally, we also tested the ability of MsaB to bind to the cap
promoter during all phases of growth under nutrient-limited conditions (CDM). We
observed that under these conditions, MsaB bound to the cap promoter during all phases
of growth (Figure. 3.8B). These findings, in addition to the those described above,
suggest that the ability of MsaB to bind to the cap promoter is altered by the binding
ability of CodY under nutrient-rich conditions. However, under nutrient-limited
conditions, MsaB is able to bind cap independently of CodY binding activity.
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Figure 3.8 Chromatin immunoprecipitation assay of MsaB binding in CDM.
(ChIP) was performed using an anti-MsaB antibody was performed to determine if the promoter region of the cap operon binds to
MsaB from whole-cell extract under (A) nutrient-depleted conditions (CDM with BCAAs vs CDM without BCAAs) in the midexponential phase of growth or (B) in CDM with BCAAs in different growth phases (early-, mid-, late-, and post-exponential phases).

As a result of the nutrient-dependent regulation of cap and msaB transcription, as
well as the observed changes in the ability of MsaB to bind cap under these nutrientlimited conditions, we tested the total capsule production under nutrient-limited growth
conditions. We compared the wild-type strain to the msaABCR, codY and
msaABCR/codY mutants grown in CDM with BCAAs or in cells shifted to CDM without
BCAAs. As mentioned above, we observed an upregulation of the cap and msaB
transcripts in the wild-type UAMS-1 strain in CDM without BCAAs relative to CDM
with BCAAs (Figure. 3.6). This correlated with a significant increase in total capsule
production (Figure. 3.9A). To confirm these findings, we quantified the intensity of the
blots using ImageJ software analysis. We found a significant increase (approximately
50%) in the total intensity of the blots in cells shifted to CDM without BCAAs compared
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to CDM with BCAAs cells (Figure. 3.9B). Interestingly, under the conditions tested, no
capsule production was detected in the codY mutant, which was different from that
observed in the nutrient-rich conditions (TSB). As a result of these findings, we tested
the total capsule production under these nutrient-depleted conditions during the lateexponential phase of growth. We observed that capsule production was detectable during
the late-exponential phase of growth under nutrient-depleted conditions in the codY
mutant (Figure. 3.9C). These results suggest that the observed binding of MsaB in the
codY mutant may not sufficiently lead to capsule being produced, or that the mutation of
codY is affecting an unknown cap regulator under these nutrient-limited conditions.
However, when the cells transition from mid-exponential growth to late-exponential
growth, MsaB binding becomes sufficient to directly activate the production of capsule
via an unknown mechanism. Taken together, these results show that MsaB and CodY are
both responsible for the complex temporal regulation and production of capsule in
response to nutrients and/or growth phase. Further studies are needed to fully understand
this complex nutrient dependent and/or growth phase dependent regulatory mechanism.
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Figure 3.9 Total capsule production in CDM compared to CDM without branched chain
amino acids and image analysis.
Total CP production in the wild-type UAMS-1 strain and the msaABCR and codY mutants along with the double msaABCR/codY
mutant to compare CP production in CDM with BCAAs vs. CDM with no BCAAs during the mid-exponential growth phase. (B)
Total CP production image analysis of the wild-type UAMS-1 strain grown in CDM with BCAAs vs. wild-type UAMS-1 grown in
CDM with no BCAAs was performed using the ImageJ analysis software. (C) Total CP production was assessed in the wild-type
UAMS-1 strain and the msaABCR and codY mutants along with the double msaABCR/codY mutant to compare CP production in
CDM with BCAAs in the late-exponential growth phase.

3.4 Discussion and Conclusions
Capsule polysaccharide is a well characterized virulence factor of S. aureus and is
involved in the evasion of phagocytic uptake during certain types of infections (19). The
regulation of capsule production in S. aureus is very complex and involves several global
regulators that tightly control the expression of cap, predominately at the transcriptional
level (94-98, 102, 132). The complexity of this regulation requires the pathogen to fine70

tune capsule expression based on environmental or host specific signals, including
nutrients and other stress related factors (19, 137). We have previously identified MsaB,
of the msaABCR operon, as a DNA-binding transcriptional activator of the cap operon
promoter. Interestingly, the binding of MsaB seemed to be either growth phasedependent or was mediated in a nutrient-dependent manner (132). In this study, we
demonstrated that, in addition to directly regulating cap, the msaABCR operon (MsaB) is
also involved in regulating two other major nutrient-dependent regulators of cap, CodY
and CcpE. The findings of this study suggest that MsaB has dual regulatory roles as a
transcriptional activator of both cap and codY and as a repressor of ccpE.
CodY has been described as a key nutrient-dependent global regulator (transcriptional
repressor) that not only regulates cap directly but also directly controls many metabolic
and virulence factors in S. aureus (70, 95, 101, 129, 135, 137, 141, 142). Pohl and
colleagues described CodY regulation of capsule in detail (101). CodY senses GTP and
branched chain amino acid (BCAA) concentrations within the growth environment of the
bacterium. The presence or absence of these nutrients results in a conformational change
within the CodY protein structure (138-140). This conformational change of the protein
results in a decrease in the DNA-binding affinity of CodY to its targets under conditions
of low nutrient concentrations (99-101). CodY is part of a four-gene operon that
produces a large 4.1 kb transcript (101). As described previously (Pohl et al., 2009), this
operon is composed of the genes xerC, clpQ, clpY, and codY. The xerC gene is thought
to encode for a tyrosine recombinase, and clpQY codes for the ATP-dependent heat shock
protease HslVU (143). Within this operon, codY can be transcribed by itself as a shorter
transcript that invades the 3’ end of the clpY encoding gene, producing a 1.4 kb transcript
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containing the codY ORF (101). Importantly, to the best of our knowledge, no other gene
has been identified to directly regulate codY transcription in S. aureus. In addition to
MsaB directly regulating codY, we also showed that MsaB and CodY putatively compete
for binding sites within the cap promoter region in a growth phase or nutrient-dependent
manner. We observed that in the codY mutant, MsaB binding is altered, resulting in
MsaB binding to the cap promoter during all phases of growth under nutrient-rich
conditions. This binding of MsaB directly led to the activation of cap and resulted in
capsule production during early- and mid-exponential phases. However, when CodY was
present in the wild type strain, under these same growth conditions MsaB did not bind to
the cap promoter, resulting in no detectable capsule production.
Many studies have described nutrients as an important factor that facilitates
capsule production within different environmental niches of S. aureus (19, 81, 85, 86).
Based on the findings of this study, we suggest that the described nutrient-dependent
binding activity of MsaB and CodY directly leads to capsule production. When nutrient
concentrations are altered, specifically in CDM in the presence or absence of BCAAs,
transcription of msaB and cap are significantly increased, and the ability of MsaB to bind
to the cap promoter is altered, resulting in MsaB binding during all phases of growth.
This binding of MsaB under nutrient-limited conditions results in capsule being
abundantly produced during mid-exponential growth phases, suggesting that the binding
of MsaB during under nutrient-limited conditions directly leads to capsule production. It
is unclear why MsaB binds to the cap promoter during all growth phases under nutrientlimited conditions, whereas under the nutrient-rich conditions, it only binds the cap
promoter during late- and post-exponential phases. This suggest that factors other than
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nutrients may be involved in the binding behavior of MsaB. Additionally, under these
same nutrient-limited conditions, there was no capsule production detected in the codY
mutant (no cap repression) in CDM with BCAAs or CDM without BCAAs. This
suggests that even though MsaB is binding under these conditions, it may not be
sufficient to completely activate cap transcription or that the mutation of codY alters
another cap regulator under these nutrient depleted conditions that leads to the inhibition
of cap production. Taken together, these results suggest that MsaB directly responds to
the concentration of nutrients, resulting in an increase in its binding ability to the cap
promoter and that under nutrient-limited conditions, the binding ability of MsaB is
independent of CodY activity. Indeed, based on amino acid sequence analysis, MsaB
appears to contain nutrient (nucleotide) binding regions, including GTP, ADP, and AMP,
suggesting that it may directly bind and respond to nucleotide or nutrient molecules.
Previously, there have been conflicting reports on the regulatory role of CcpE
with respect to cap regulation. As mentioned above, Ding et al. described ccpE as a direct
repressor of the cap operon (97). However, Hartmann et al. described ccpE as promoting
capsule formation in S. aureus, but described CcpE as not directly binding to the cap
promoter (97, 134). In our study, we observed that ccpE promotes capsule formation.
However, under the conditions tested, we did not find any evidence of CcpE directly
binding to the cap promoter, suggesting that the regulatory effect of CcpE with respect to
cap is not direct and may be dependent upon another cap regulator. Importantly, under
the conditions tested, the ccpE mutation, which resulted in a significant decrease in cap
transcript and total capsule production, the msaB transcript (cap activator) was
significantly downregulated (-6.0-fold). These results suggest that the observed effect on
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capsule production resulting from the mutation of ccpE may be dependent on the
regulatory effect that the mutation has on the msaB transcript under these conditions.
Additionally, another interesting finding observed in this work, with respect to MsaB and
CcpE, is that in the msaABCR/ccpE double mutant, even though significantly decreased,
there was still detectable capsule production, similar to what was observed in the ccpE
mutant alone. These findings suggest that ccpE may be epistatic to msaB. However, this
seems to contradict our findings that MsaB represses the transcription of ccpE (Figure.
3.3A). This indicates that the regulatory relationship between msaABCR, ccpE, and cap
is complex and may involve other factors. Further studies are necessary to better
understand these interactions.
This work focused on the nutrient dependent regulation of capsule production in
S. aureus with respect to the nutrient-dependent regulators MsaB, CodY, and CcpE. The
findings from this work suggest that cap regulators CodY (repressor) and MsaB
(activator) both directly respond to changes in nutrients within the environment of the
bacterium and in turn tightly control cap expression and ultimately the production of
capsule polysaccharide. However, many other regulators and factors are responsible for
the control of capsule production that do not have a known direct link to nutrients. Based
on previous studies and the results of this work, we propose a regulatory model that
describes how MsaB and CodY control capsule production (Figure. 3.10). In this model,
we propose that under high nutrient conditions, CodY is bound to the cap promoter
region, repressing the cap promoter (Figure. 3.10A). However, as nutrients become
limited, the binding affinity of CodY decreases as a result of a conformation change in
the CodY protein structure, resulting in the loss of transcriptional repression. Under
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conditions when CodY is not bound to the cap promoter, MsaB binding site is available,
allowing for MsaB to bind to and activate the cap promoter (Figure. 3.10B). This
proposed regulatory mechanism suggests that complex regulatory interactions occur
between CodY and MsaB as a direct response to nutrient availability.
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Figure 3.10 Working model for cap operon regulation by MsaB and CodY.
(A) When nutrients are abundant, CodY binds to the CodY-binding site (CBS) in the promoter region of the cap operon and represses
cap transcription. (B) When nutrient levels decrease, a conformational change in the CodY structure occur, resulting in a decrease in
the affinity of CodY for the promoter. Detachment of CodY from the promoter allows MsaB to access the MsaB-binding site (MBS).
In addition, MsaB appears to have a greater binding ability under low nutrient levels. Binding of MsaB activates the transcription of
the cap operon.

The regulatory control of capsule production described in this work by both MsaB
and CodY are representative of a mixture of incoherent feed-forward loops or (FFLs).
This type of regulatory mechanism is defined as consisting of three genes: a regulatory
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gene X that regulates gene Y, and gene Z (Figure. 3.11A). The gene Z promoter is
regulated by both X and Y as well as X regulating gene Z independent of Y (144, 145).
In our case, MsaB directly regulates both the cap operon (activation) and codY, which in
turn regulates capsule production. This is representative of an incoherent type 1 FFL
(Figure. 3.11B). Alternatively, CodY directly regulates both capsule production
(repression) and msaB, which subsequently regulates capsule production and is
representative of an incoherent type 3 FFL (Figure. 3.11C). These regulatory interactions
allow both regulators to coordinately control the cap promoter and ultimately capsule
production. Furthermore, the findings from this work suggest that this regulatory control
of capsule production by MsaB and CodY is dependent on the growth phase and/or
nutrient stimuli in S. aureus. Additionally, both CodY and MsaB have also been
described to have roles in the regulation of other virulence determinants in S. aureus (63,
65, 70, 95, 101, 129, 132, 135, 141, 142, 146). Findings from this work may have
implications in the interaction of S. aureus with the host during the transition from a
commensal to a pathogenic form. Studies are underway to investigate if the described
regulatory mechanism between CodY and MsaB is responsible for the regulatory control
of other virulence mechanisms possessed by S. aureus.
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Figure 3.11 Incoherent feed-forward loops (FFLs) representing regulation of capsule
production by MsaB and CodY.
(A) Examples of the four different types of incoherent FFLs are shown that describe two regulators “X” and “Y” (activators or
repressors) controlling one gene “Z”. (B) Highlights the incoherent type 1 FFL with respect to MsaB regulation on capsule production
as well as the codY transcript. (C) Highlights the incoherent type 3 FFL with respect to CodY regulation on capsule production as
well as on the msaB transcript.
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Table 3.4 Lists of Primers used in this study.
Primers

Sequence (5’ → 3’ end)

Primers for Real Time PCR
RT gyrA F

GCCGTCAGTCTTACCTGCTC

RT gyrA R
RT capE F

AATAACGACACGCACACCAG
ACATTGGTGATGTGCGTGAT

RT capE R
RT airR F

TCACATGACGGCACTTGTTT
TGCTGATGGTTATGAAATGA

RT airR R
RT airS F

CATCTTGTGCCTTAGGATGT

RT airS R

TTCCTAGCCAAAATGACAATA
TTCAGTATTTGGAGACGCTAC

RT ccpE F
RT ccpE R

GGGTGTTCTTCTTTGATTGG
TTGAACCAACTTGCACTTGT

RT codY F
RT codY R

ATCGCATCAAAAGTTGCAGA
CGTGATTCAATTACACCAGCA

RT kdpD F
RT kdpD R

TACCACACCATTTCAAGTTAGA

RT kdpE F

GTTAAACGAGAGGATTTTTGAG
AATTCAAAGTCGTTTCACAAA

RT kdpE R
RT rbsR F

GAATTCATTCGGTGTTAGATG
TATCGCACAATACATATCATCC

RT rbsR R
RT spoVG F

GTATAGCCTTGATGGTCATTTT
AGCACTCGTTTCCATTACAT

RT spoVG R

TGTACGTTTACTTGGCATTG

Primers for ChIP and EMSA
cap-ChIP F
cap-ChIP R

CTACTTTAGAGTATAATTATTTTTAATTTC
CCCTTAAAAATTTTCATTAAAATTG

codY-ChIP F
codY-ChIP R

TTTCCATGTATCTAAGCCGAG

codY operon F

CATCAACATATTGTGGGGTAAT
TAAATAACACGCAATAAGTTGATTG

codY operon R
ccpE-ChIP F

CTTGAATATGATTCAATACATTTAC
GTAATTCAAGCTGCAGCCATG

ccpE-ChIP R

TCGCTCTCTTTTCAACATGTCAC

Primers for 6XHIS-complement constructs
6XHIS-codY comp
F
6XHIS-codY comp
R
6XHIS-ccpE comp
F
6XHIS-ccpE comp
R

ATCAGGGATCCATGCATCATCACCATCACCACAGCTTATTATCTAAAACGAG
ATGTGAATTCTTATTTACTTTTTTCTAATTCATCTAAG
ATCAGGGATCCATGCATCATCACCATCACCACATGATTATTGAGCATGCCCGTGA
ATGTGAATTCCTACGCCTTTGGTTGTTCAACAAA
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CHAPTER IV – CONCLUSIONS AND FUTURE DIRECTIONS
In this work we have established that MsaB of the msaABCR operon is a DNAbinding transcriptional regulator. Within the context of this work we have characterized
the role of the MsaB transcription factor binding to and activating the cap promoter
region within S. aureus. This work has been further expanded to investigate the
mechanisms involved in this DNA binding and transcriptionally activating capsule
polysaccharide, an accessory virulence phenotype for S. aureus. We found that MsaB
seems to be interacting with another well studied transcriptional regulator, CodY, in
response to nutrient availability. Our findings suggest that MsaB and CodY have
nutrient-dependent competitive interactions binding to the cap promoter region. When
nutrient concentrations are depleted MsaB binds to the cap promoter and activates
transcription. In turn, our findings suggest that CodY represses cap transcription under
high nutrient conditions by binding to the cap promoter region as a repressor, as well as
potentially blocking the MsaB binding site. Additionally, evidence suggest that MsaB,
through an undetermined mechanism, may be potentially sensing low nutrient levels
controlling its binding affinity to the cap promoter. Taken together these results suggest
that MsaB binding the cap promoter contributes to the nutrient-dependent regulation of
capsule in S. aureus.
In addition to the cap transcript the deletion of the msaABCR operon results in the
differential expression (>3-fold) of 238 genes, including 20 transcription factors, during
both planktonic and biofilm growth. To date, the mechanisms of this regulation is still
unclear. However, of the 238 genes differentially expressed, we have found that 112 of
those genes contain a sequence in their promoter regions that is similar to the MsaB
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binding site described in this work. Moving forward, we plan to investigate the potential
of MsaB binding to and directly controlling the transcription of this large array of genes
within staphylococci.
Moving forward, we have begun to develop a precise binding assay to further
expand our understanding of MsaB binding to its target DNA (Figure 4.1). Using a
modified fluorescence resonance energy transfer (FRET) based assay known as
homogenous time resolved fluorescence (HTRF) we can measure MsaB binding
parameters in detail (Figure 4.2). Briefly, this method can be utilized to precisely
determine the binding constant of MsaB binding its target DNA, determine the role of
nutrient molecules or potential cofactors in MsaB binding, and determine potential
competitive interactions between MsaB and other regulators such as CodY. After the
detailed MsaB DNA-binding parameters are determined we can use this same HTRF
approach to perform a high-throughput screen of inhibitory molecules of MsaB DNAbinding. Completion of a MsaB binding inhibitory screen, as described, will provide
preliminary insights in the potential of targeting the MsaB regulator as a novel
therapeutic target of staphylococci.
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Figure 4.1 HTRF binding assay model.
Binding of MsaB to its target DNA will be detected by measuring fluorescence generated from an energy transfer between a donor
molecule (europium cryptate Eu-K) and an acceptor molecule (phycobilliprotein XL665).

Figure 4.2 HTRF MsaB binding signal.
Preliminary results demonstrating the energy transfer (FRET) from the donor molecule (europium cryptate) to the acceptor molecule
(XL665) due to the binding of MsaB to the DNA probe compared to a control experiment of DNA probe alone (no energy transfer).
Binding of MsaB to its target DNA will be detected by measuring fluorescence generated from an energy transfer between a donor
molecule (europium cryptate Eu-K) and an acceptor molecule (phycobilliprotein XL665).
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